

US 20200101108A1

(19) **United States**

(12) **Patent Application Publication**  
**LYNN et al.**

(10) **Pub. No.: US 2020/0101108 A1**

(43) **Pub. Date: Apr. 2, 2020**

(54) **METHODS OF TREATING T CELL  
EXHAUSTION BY INHIBITING OR  
MODULATING T CELL RECEPTOR  
SIGNALING**

(71) Applicant: **THE BOARD OF TRUSTEES OF  
THE LE-LAND STANDFORD  
JUNIOR UNIVERSITY**, Stanford, CA  
(US)

(72) Inventors: **Rachel LYNN**, Stanford, CA (US);  
**Crystal MACKALL**, Stanford, CA  
(US); **Evan WEBER**, Stanford, CA  
(US); **Sanjay MALHOTRA**, Stanford,  
CA (US)

(21) Appl. No.: **16/499,762**

(22) PCT Filed: **Mar. 30, 2018**

(86) PCT No.: **PCT/US2018/025394**

§ 371 (c)(1),

(2) Date: **Sep. 30, 2019**

**Related U.S. Application Data**

(60) Provisional application No. 62/479,930, filed on Mar.  
31, 2017.

**Publication Classification**

(51) **Int. Cl.**

**A61K 35/17** (2006.01)

**A61K 31/5025** (2006.01)

**A61K 31/506** (2006.01)

**C07K 16/30** (2006.01)

**C12N 5/0783** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 35/17** (2013.01); **A61K 31/5025**  
(2013.01); **A61K 31/506** (2013.01); **C07K**  
**16/3084** (2013.01); **C12N 2510/00** (2013.01);  
**C07K 2317/622** (2013.01); **C07K 2319/03**  
(2013.01); **C07K 2319/33** (2013.01); **C12N**  
**2501/727** (2013.01); **C12N 5/0636** (2013.01)

(57)

**ABSTRACT**

Provided herein are compositions and methods for prevent-  
ing or reversing T cell exhaustion. In particular, the present  
invention relates to methods of preventing or reversing T  
cell exhaustion by exposing T cells experiencing T cell  
exhaustion to particular tyrosine kinase inhibitors (e.g.,  
dasatinib, ponatinib), or by expanding genetically engi-  
neered T cells in the presence of particular tyrosine kinase  
inhibitors (e.g., dasatinib, ponatinib).

**Specification includes a Sequence Listing.**





FIG. 1




FIG. 2




FIG. 3

\*Data collected on day 14, gated on CD8+




FIG. 4






FIG. 5




FIG. 6




FIG. 7




FIG. 8






FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13




FIG. 14






FIG. 15A




FIG. 15B




FIG. 16




FIG. 17




FIG. 18






FIG. 19




FIG. 20A




FIG. 20B




FIG. 21




FIG. 22A




FIG. 22B






FIG. 22C




FIG. 22D




FIG. 22E




FIG. 23

**CD19.28z (FMC63 scFv)**

Nucleic acid sequence (SEQ ID NO:1)

ATGACAAGAGTTACTAACAGCCCCTCTCTCCAAGCTCACTTACAGGCTCTCTACTTAGTCCAGCAC  
GAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACCTGGACCGACCGGTGGTACCTCACCC  
TTACCGAGTCGGCGACACAGTGTGGGTCCGCCGACACCAGACTAAGAACCTAGAACCTCGCTGGA  
AAGGACCTTACACAGTCCTGCTGACCACCCCCACCGCCCTCAAAGTAGACGGCATCGCAGCTTGG  
ATACACGCCGCCACGTGAAGGCTGCCGACCCCGGGGGTGGACCATCCTCTAGACTGCTCGAGAT  
GCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGAC  
ATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGC  
AGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTAA  
ACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTTCAGTGGCAGTGGGTC  
TGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCA  
ACAGGGTAATACGCTTCCGTACACGTTCCGAGGGGGGACTAAGTTGGAAATAACAGGCTCCACCT  
CTGGATCCGGCAAGCCCGGATCTGGCGAGGGATCCACCAAGGGCGAGGTGAAACTGCAGGAGTCA  
GGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTCAGGGGTCTCATT  
CCCGACTATGGTGTAAGCTGGATTTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAAT  
ATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACA  
ACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACCTGATGACACAGCCATTTACTACT  
GTGCCAAACATTATTACTACGGTGGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCA  
CCGTCTCCTCAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCA  
ATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTA  
AGCCCTTTTGGGTGCTGGTGGTGGTTGGGGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGG  
CCTTTATTATTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGA  
CTCCCCGCCGCCCGGGCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAG  
CCTATCGCTCCAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAAC  
CAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGG  
CCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAA  
CTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGG  
GCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTT  
CACATGCAGGCCCTGCCCCCTCGCTAA

Amino acid sequence (SEQ ID NO:2)

MTRVTNSPSLQAHLLQALYLQHEVWRPLAAAYQEQLDRPVVPHYPYRVGDTVWVRRHQTKNLEPRW  
KGPYTVLLTTPTALKVDGIAAWIHAHVKAADPGGGPSSRLLEMLLLVTSLLLCELPHPAFLIPDIQM  
TQTTSSLASLGDRVTISCRASQDISKYLNWYQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLT  
ISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSL  
VTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWGSSETTYNSALKSRLTIKDNSKSQVFLKMNSLQTD  
DTAIYYCAKHYYYGGSYAMDYWGQGSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPF  
PGPSKPFVVLVVVGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYQPYAPPRD  
FAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYN  
ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR\*



FIG. 24

**CD19.BBz (FMC63 scFv)**

Nucleic acid sequence (SEQ ID NO:3)

ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCTCCTGATCCCAG  
ACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTT  
GCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAAGTGT  
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTTCAAGTGGCAGTGGG  
TCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGC  
CAACAGGGTAATACGCTTCCGTACACGTTCCGAGGGGGGACTAAGTTGGAAATAACAGGCTCCAC  
CTCTGGATCCGGCAAGCCCGGATCTGGCGAGGGATCCACCAAGGGCGAGGTGAAACTGCAGGAGT  
CAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTCAGGGGTCTCAT  
TACCCGACTATGGTGTAAGCTGGATTCCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTA  
ATATGGGGTAGTGAAACCACATACTATAATTGAGTCTCAAATCCAGACTGACCATCATCAAGGAC  
AACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAATGATGACACAGCCATTTACTAC  
TGTGCCAAACATTATTACTACGGTGGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTC  
ACCGTCTCCTCAGCGGCCGCAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCAACAT  
CGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACA  
CGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGCGCCGGGACTTGTGGGGTCC  
TTCTCCTGTCACTGGTTATCACCCCTTACTGCAAACGGGGCAGAAAGAACTCCTGTATATATTCA  
AACAAACATTTATGAGACCAGTACAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCA  
GAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGT  
ACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTT  
TTGGACAAGAGACGTGGCCGGGACCCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGG  
AAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAA  
AGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAG  
GACACCTACGACGCCCTTACATGCAGGCCCTGCCCCCTCGCTAA

Amino acid sequence (SEQ ID NO:4)

MLLLVTSLLLCELPHPAFLIPDIQMTQTSSLSASLGDRVITISCRASQDISKYLNWYQQKPDGTVKLLI  
YHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGKLEITGSTSGSGKPGSG  
EGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVWGSSETTYNSA  
LKSRLTIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGSVTVSSAAATTPAP  
RPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKL  
LYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYD  
VLDKRRGRDPGEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD  
TYDALHMQALPPR\*



FIG. 25

**GD2.BBz (14G2a scFv)**

Nucleic acid sequence (SEQ ID NO:5)

ATGCTGCTGCTCGTGACATCTCTGCTGCTGTGCGAGCTGCCCCACCCCGCCTTTCTGCTGATCCCCG  
 ATATCCTGCTGACCCAGACCCCTCTGAGCCTGCCTGTGTCTCTGGGCGATCAGGCCAGCATCAGCT  
 GCAGATCCAGCCAGAGCCTGGTGCACCGGAACGGCAACACCTACCTGCACTGGTATCTGCAGAAG  
 CCCGGCCAGAGCCCCAAGCTGCTGATTACAAGGTGTCCAACCGGTTTCAGCGGCGTGCCCGACAG  
 ATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACC  
 TGGGCGTGTACTTCTGCAGCCAGTCCACCCACGTGCCCCCCTGACATTTGGCGCCGGAACAAAGC  
 TGGAAGTGAAGGGCAGCACAAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGG  
 CGAAGTGAAGCTGCAGCAGAGCGGCCCTCTCTGGTGGAACTGGCGCCTCTGTGATGATCTCCTG  
 CAAGGCCAGCGGCAGCTCCTTCACCGGCTACAACATGAACTGGGTGCGCCAGAACATCGGCAAGA  
 GCCTGGAATGGATCGGCGCCATCGACCCCTACTACGGCGGCACCAGCTACAACCAGAAGTTCAAG  
 GGCAGAGCCACCCTGACCGTGGACAAGAGCAGCTCCACCGCCTACATGCACCTGAAGTCCCTGAC  
 CAGCGAGGACAGCGCCGTGTACTACTGCGTGTCCGGCATGGAATACTGGGGCCAGGGCACAAAGCG  
 TGACCGTGTCTCTGCGGCGCGCAACCACGACGCCAGCGCCGCGACCAACACCGGCGCCACC  
 ATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCA  
 CACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGT  
 CCTTCTCCTGTCACTGGTTATCACCTTTACTGCAAACGGGGCAGAAAGAACTCCTGTATATATTC  
 AAACAACCATTATGAGACCAGTACAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCC  
 AGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCG  
 TACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGT  
 TTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAG  
 GAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGA  
 AAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA  
 GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAA

Amino acid sequence (SEQ ID NO:6)

MLLLVTSLLLCELPHPAFLIPDILLTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSP  
 KLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKGSTSGS  
 GKPGSGEGSTKGEVKLQQSGPSLVEPGASVMISCKASGSSFTGYNMNWVRQNIKGSLEWIGAIDPYYG  
 GTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSSAAATTPAPR  
 PPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKLL  
 YIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDV  
 LDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT  
 YDALHMQALPPR\*

FIG. 26

**HA-GD2.28z (High affinity 14G2a scFv)**

Nucleic acid sequence (SEQ ID NO:7)

ATGGAATTCGGCCTGAGCTGGCTGTTCTTGGTGGCCATCCTGAAGGGCGTGCAGTGCAGCAGAGA  
TATCCTGCTGACCCAGACCCCTCTGAGCCTGCCTGTGTCTCTGGGCGATCAGGCCAGCATCAGCTG  
CAGATCCAGCCAGAGCCTGGTGCACCGGAACGGCAACACCTACCTGCACTGGTATCTGCAGAAGC  
CCGGCCAGAGCCCCAAGCTGCTGATCCACAAGGTGTCCAACCGGTTTCAGCGGCGTGCCCGACAGA  
TTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCCTGAAGATCAGCCGGGTGGAAGCCGAGGACCT  
GGGCGTGTACTTCTGCAGCCAGTCCACCCACGTGCCCCCCTGACATTTGGCGCCGGAACAAAGCT  
GGAAGTGAAGGGGGGAGGCGGATCTGGCGGCGGAGGAAGTGGCGGAGGGGGATCTGAAGTGAAG  
CTGCAGCAGTCCGGCCCCAGCCTGGTGGAACTGGCGCCTCTGTGATGATCTCCTGCAAGGCCAGC  
GGCAGCTCCTTCACCGGCTACAACATGAAGTGGGTGCGCCAGAACATCGGCAAGAGCCTGGAATG  
GATCGGCGCCATCGACCCCTACTACGGCGGCACAGCTACAACCAGAAGTTCAAGGGCAGAGCCA  
CCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGCACCTGAAGTCCCTGACCAGCGAGGAC  
AGCGCCGTGTACTACTGCGTGTCCGGCATGAAGTACTGGGGCCAGGGCACAAGCGTGACCGTGTG  
TAGCGCCAAGACCACCCCCCTAGCGTGTACGGAAGAGTGACAGTGTCTCTGCCGAGCCCAAGA  
GCTGCGACAAGACCACACCTGTCCCCCTTGTCTTGGCCCTGAGCTGCTGGGAGGCCCTTCCGTGT  
TCCTGTTCCCCCAAAGCCCAAGGACACACTGATGATCAGCAGAACCCCCGAAGTGACCTGCGTG  
GTGGTGGACGTGTCCACGAGGACCCAGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGT  
GCACAACGCCAAGACAAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTG  
CTGACCGTGTGTCATCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAAGTGTCCAACAAGGC  
CCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGT  
ACACACTGCCCCCTAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACATGCCTCGTGAAG  
GGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACACTACAA  
GACAACCCCTCCCGTGCTGGACAGCGACGGCTCATTCTTCTGTACAGCAAGCTGACAGTGGATAA  
GTCCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACT  
ACACCCAGAAAAGCCTGTCCCTGAGCCCCGGCAAGAAGGACCCCAAAGCTAGCTTCGAAATTGAA  
GTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTGAAAGGG  
AAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTG  
GGGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTA  
AGAGGAGCAGGCTCCTGCACAGTGAATGACATGAACATGACTCCCCGCCGCCCGGGCCACCCGC  
AAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCAGAGTGAAGTTCAGC  
AGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGG  
ACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAG  
CCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGG  
CCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGGCAAGGGGCACGATGGCCTTTACCA  
GGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTA  
A

Amino acid sequence (SEQ ID NO:8)

MEFGLSWLFLVAILKGVQCSDILLTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQS  
PKLLIHKVSNRFSVGPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKGGGGS  
GGGGSGGGGSEVKLQQSGPSLVEPGASVMISCKASGSSFTGYNMNWVRQNIKGSLEWIGAIDPYGGT  
SYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMKYWGQGTSTVTVSSAKTTPPSVYGRV  
TVSSAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV  
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP  
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS  
RWQQGNVFSCSVMHEALHNHYTQKLSLSLSPGKKDPKASFEIEVMYPPPYLDNEKSNGTIIHVKGKHL  
PSPLFPGPSKPFWVLVVVGGLVACYSLLVTVAFIIFWVRSKRSLHSDYMNMTPRRPGPTRKHYPY  
APPRDFAAYRSRVKFSRSADAPAYKQGQNLNELNLGRREEYDVLDRGRDPEMGGKPRRKNPQE  
GLYNELQKDKMAEAYSEIGMKGERRRGKGHDLGYQLSTATKDTYDALHMQALPPR\*



# METHODS OF TREATING T CELL EXHAUSTION BY INHIBITING OR MODULATING T CELL RECEPTOR SIGNALING

## CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application Ser. No. 62/479,930, filed Mar. 31, 2017, which is incorporated herein by reference in its entirety.

## FIELD OF THE INVENTION

[0002] Provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).

## INTRODUCTION

[0003] T cells are immune cells that become activated via T cell receptor (TCR) signaling following engagement with antigen. Physiologic activation through the T cell receptor renders T cells capable of mediating potent antitumor or anti-infective effects. During resolution of an acute inflammatory response, a subset of activated effector T cells differentiate into long-lived memory cells. By contrast, in patients with chronic infections or cancer, T cells not infrequently undergo pathologic differentiation toward a state of dysfunction, which has been termed T cell exhaustion. T cell exhaustion is characterized by marked changes in metabolic function, transcriptional programming, loss of effector function (e.g., cytokine secretion, killing capacity), and co-expression of multiple surface inhibitory receptors. The root cause of T cell exhaustion is persistent antigen exposure leading to continuous TCR signaling. Prevention or reversal of T cell exhaustion has been long sought as a means to enhance T cell effectiveness in patients with cancer or chronic infections.

[0004] The present invention addresses this urgent need.

## SUMMARY OF THE INVENTION

[0005] Immune cells respond to the presence of foreign antigens with a wide range of responses, including the secretion of preformed and newly formed mediators, phagocytosis of particles, endocytosis, cytotoxicity against target cells, as well as cell proliferation and/or differentiation. T cells are a subgroup of cells which together with other immune cell types (e.g., polymorphonuclear, eosinophils, basophils, mast cells, B cells, and NK cells), constitute the cellular component of the immune system (see, e.g., U.S. Pat. No. 6,057,294; US Pat. Appl. 20050070478). Under physiological conditions T cells function in immune surveillance and in the elimination of foreign antigen. However, under pathological conditions there is compelling evidence that T cells play a major role in the causation and propagation of disease. In these disorders, breakdown of T cell immunological tolerance, either central or peripheral is a fundamental process in the causation of autoimmune disease.

[0006] It is well established that T cell receptor (TCR) engagement and costimulatory signaling provide the critical signals that regulate T cell activation, proliferation and cytolytic functions. T cells respond to antigen via a polypeptide complex composed of the ligand-binding T cell receptor (TCR) disulfide-linked  $\alpha$  and  $\beta$  subunits (or  $\gamma$  and  $\delta$  subunits in  $\gamma\delta$  T cells) that have single transmembrane (TM) spans per subunit and small intracellular tails and associate non-covalently with hetero- (CD3 $\gamma\epsilon$  and CD3 $\delta\epsilon$ ) and homodimeric ( $\zeta\zeta$ ) signaling subunits (see, e.g., Cambier J. C. *Curr Opin Immunol* 1992; 4:257-64). The CD3 $\epsilon$ ,  $\delta$ , and  $\gamma$  chains have single Ig-family extracellular domains, single presumably  $\alpha$ -helical TM spans, and intrinsically disordered intracellular domains of 40-60 residues, whereas each subunit has a small extracellular region (9 residues) carrying the intersubunit disulfide bond, a single presumably  $\alpha$ -helical TM span per subunit, and a large, intrinsically disordered cytoplasmic domain of approximately 110 residues. An understanding of the process of TCR-mediated TM signal transduction and subsequent T cell activation, leading to T cell proliferation and differentiation, is therefore pivotal to both health and disease. Disturbance in TCR signaling can lead to inflammatory and other T cell-related disorders.

[0007] T cells expressing chimeric antigen receptors (CARs) at high levels undergo tonic, antigen independent signaling due to receptor clustering. Such T cells function poorly as a result of T cell exhaustion, as evidenced by high levels of PD-1, TIM-3, LAG-3, diminished antigen induced cytokine production, and excessive programmed cell death. Tonic signaling can be prevented by transiently decreasing CAR associated TCR signaling proteins (e.g., TCR zeta) to levels below the threshold required for tonic signaling.

[0008] Experiments conducted during the course of developing embodiments for the present invention demonstrated that treatment with a particular tyrosine kinase inhibitor that inhibits T cell receptor signaling (e.g., a Lck tyrosine kinase inhibitor (e.g., dasatinib)) (e.g., a Src family tyrosine kinase inhibitor) reduced expression of the T cell exhaustion markers and improved formation of T cell memory. Accordingly, the present invention relates to methods of preventing or reversing T cell exhaustion by transiently inhibiting T cell receptor (TCR) signaling to restore T cell function with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).

[0009] Additional experiments determined that CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation, fail to secrete cytokine, and display attenuated killing in response to tumor antigen.

[0010] Additional experiments determined that dasatinib potently inhibits the phosphorylation of CAR CD3 $\zeta$  as well as distal signaling proteins after CAR crosslinking.

[0011] Additional experiments determined that tonically signaling CAR T cells expanded in the presence of dasatinib exhibit a reduction in canonical exhaustion marker expression in a dose-dependent manner, retain the capacity to form memory, display augmented cytokine secretion in response to tumor antigen, and display augmented cytotoxicity.

[0012] Additional experiments determined that in vivo dasatinib treatment suppresses exhaustion marker expression, augments memory formation, and facilitates cell survival/proliferation.

[0013] Accordingly, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In



particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).

**[0014]** In certain embodiments, the present invention provides methods for treating a subject to mitigate T cell exhaustion, the method comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic.

**[0015]** Such methods are not limited to a particular manner of treating the subject for T cell exhaustion. In some embodiments, the treatment increases secretion of IL-2 by T cells in the subject. In some embodiments, the treatment decreases apoptosis of T cells in the subject. In some embodiments, the treatment decreases expression of at least one T cell exhaustion marker selected from the group consisting of PD-1, TIM-3, and LAG-3. In some embodiments, the treatment increases expression of CD62L or CCR7.

**[0016]** Such methods are not limited to particular manner of administration. In some embodiments, multiple cycles of treatment are administered to the subject. In some embodiments, the tyrosine kinase inhibitor is administered intermittently. In some embodiments, the tyrosine kinase inhibitor is administered for a period of time sufficient to restore at least partial T cell function then discontinued. In some embodiments, the tyrosine kinase inhibitor is administered orally.

**[0017]** Such methods are not limited to a particular type or kind of subject. In some embodiments, the subject is a human. In some embodiments, the subject has a chronic infection or cancer.

**[0018]** In certain embodiments, the present invention provides for treating an immune system related condition or disease in a subject comprising administering to the subject genetically engineered T cells and a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic. In some embodiments, the tyrosine kinase inhibitor and the genetically engineered T cells are administered simultaneously and/or at different time points.

**[0019]** Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not

limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0020]** Such methods are not limited to treating a specific immune system related condition or disease. In some embodiments, the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.

**[0021]** In certain embodiments, the present invention provides methods for preventing and/or reversing toxicity related to genetically engineered T cell administered to a subject, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib.

**[0022]** Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0023]** Such methods are not limited to a particular type or kind of adoptive T cell therapy. In some embodiments, the adoptive T cell therapy is a CAR T-cell therapy. In some embodiments, the adoptive T cell therapy is a transduced T-cell therapy. In some embodiments, the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.

**[0024]** Such methods are not limited to a particular type or kind of toxicity related to genetically engineered T cell administered to a subject. In some embodiments, the toxicity related to genetically engineered T cell administered to a subject is cytokine release syndrome. In some embodiments, the toxicity related to genetically engineered T cell administered to a subject is on-target off tumor toxicity or off-target off-tumor toxicity.

**[0025]** In certain embodiments, the present invention provides compositions comprising a genetically engineered T cell population, wherein the genetically engineered T cell population was expanded in the presence of tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor. In some embodiments, the tyrosine kinase inhibitor dasatinib or ponatinib.

**[0026]** In certain embodiments, the present invention provides methods of generating a population of genetically engineered T cells resistant to T cell exhaustion, comprising expanding a population of genetically engineered T cells in the presence of a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or



ponatinib. Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR. Such methods are not limited to a specific expanding technique as such techniques are well known in the art.

**[0027]** In certain embodiments, the present invention provides methods of treating an immune system related condition or disease in a subject undergoing an adoptive T cell therapy, comprising administering to the subject a genetically engineered T cell population that were expanded in the presence of a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling inhibitor and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.

**[0028]** Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0029]** Such methods are not limited to a particular type or kind of adoptive T cell therapy. In some embodiments, the adoptive T cell therapy is a CAR T-cell therapy. In some embodiments, the adoptive T cell therapy is a transduced T-cell therapy. In some embodiments, the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.

**[0030]** The present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies. In such embodiments, the methods result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population. Thus, the present invention provides methods for treating cancer (e.g., and/or cancer related disorders) with adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating

lymphocyte (TIL) therapy) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells, particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and additional cancer therapeutic drugs or radiation therapies.

**[0031]** The present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies. In such embodiments, the methods result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides methods for treating cancer (e.g., and/or cancer related disorders) with adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and additional cancer therapeutic drugs or radiation therapies.

**[0032]** The present invention contemplates that such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.

**[0033]** In certain embodiments of the invention, combination treatment of animals with such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) produce a greater tumor response and clinical benefit in such animals compared to those treated with the anticancer drugs/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with such methods.

**[0034]** A non-limiting exemplary list of cancer (e.g., and/or cancer related disorders) includes, but is not limited to, pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma,



ovarian cancer, brain cancer, primary brain carcinoma, head and neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma, and the like, T and B cell mediated autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative conditions, vascular diseases, and the like. In some embodiments, the cancer cells being treated are metastatic. In other embodiments, the cancer cells being treated are resistant to anticancer agents.

#### BRIEF DESCRIPTION OF DRAWINGS

**[0035]** FIG. 1: Characterization of the GD2.28z.FKBP CAR. T cells were transduced with lentivirus encoding the GD2.28z.FKBP CAR on day 1 after activation and subsequently cultured with various concentrations of shield-1 in the growth medium. On day 7, CAR expression was quantified via FACS.

**[0036]** FIG. 2: Removal of S1 from culture medium results in reversal of T cell exhaustion marker surface expression.

**[0037]** FIG. 3: Removal of S1 from culture medium results in maintenance of CD62L expression and prevention of apoptosis.

**[0038]** FIG. 4: Removal of S1 from culture medium results in reversal of function T cell exhaustion.

**[0039]** FIG. 5: Removal of surface CAR results in more effective prevention of T cell exhaustion compared PD-1/PDL-1 blockade.

**[0040]** FIG. 6: Removal of surface CAR rescues exhaustion in PD-1/TIM-3/LAG-3 triple positive CAR T cells after only 4 days.

**[0041]** FIG. 7: Dasatinib inhibits cytokine secretion of CAR T cells in response to tumor antigen.

**[0042]** FIG. 8: Dasatinib reverses exhaustion marker expression and co-expression.

**[0043]** FIG. 9: Dasatinib treatment results in maintenance of CD62L expression.

**[0044]** FIG. 10: Dasatinib Treatment results in augmented IL-2 and IFN $\gamma$  secretion in response to tumor antigen.

**[0045]** FIG. 11: CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation. As shown, CD19.28z CAR T cells were cultured in the presence or absence of various concentrations of dasatinib or ponatinib for at least 48 hours. CAR T cells were then co-cultured with CD19-bearing Nalm6 tumor cells for 6 hours. CD69 and CD107a surface

expression was subsequently assessed via FACS. Plots display cells gated on the CD8+ CAR+ population. Such results demonstrate that 80% of CD19.28z CART cells become activated (surface CD69 is a surrogate for activation) and degranulate (surface CD107a is a surrogate for degranulation) in response to tumor. However, dasatinib and ponatinib dose-dependently inhibit CAR T cells' ability to respond to tumor in this manner.

**[0046]** FIG. 12: CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib fail to secrete cytokine. As shown, high affinity GD2.28z (HA-GD2.28z) CAR T cells were co-cultured with GD2-overexpressing nalm6 for 24 hours in the presence or absence of various concentrations of dasatinib or ponatinib. Supernatant was then collected and analyzed for IL-2 and IFN $\gamma$  via ELISA. These results demonstrate that using the HA-GD2.28z CAR, dasatinib and ponatinib inhibit CART cell secretion of IL-2 and IFN $\gamma$  in response to tumor.

**[0047]** FIG. 13: CAR T cells cultured in the presence of dasatinib display attenuated killing in response to tumor antigen. An incucyte assay was conducted in which CD19.28z CAR T cells were co-cultured with nalm6 tumor cells expressing a GFP reporter for 72 hours in the presence of 1  $\mu$ M dasatinib or vehicle (DMSO). Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point. These results demonstrate that dasatinib blunts the ability of the CD19.28z CAR to kill tumor cells. FIGS. 11, 12 and 13 demonstrate that dasatinib or ponatinib could serve as a rapid and reversible safety "OFF" switch for CAR T cells that are having deleterious effects in a given patient.

**[0048]** FIG. 14: Dasatinib potently inhibits the phosphorylation of CAR CD3z as well as distal signaling proteins after CAR crosslinking. 2E6 HA-GD2.28z CAR T cells cultured in 1  $\mu$ M dasatinib or vehicle were removed from culture on day 10 post-activation. Idiotypic primary antibody and a crosslinking secondary antibody were then added to the cells at 5  $\mu$ g/mL to initiate signaling through the CAR. Shown here, dasatinib potently inhibits crosslinking-induced phosphorylation of the CD3z domain on the CAR, as well as phosphorylation of distal signaling kinases Akt and ERK1/2. This is a representative blot of n=3 independent experiments.

**[0049]** FIG. 15: Tonically signaling CART cells expanded in the presence of dasatinib exhibit a reduction in canonical exhaustion marker expression in a dose-dependent manner. HA-GD2.28z CART cells were expanded in the presence of various concentrations of dasatinib or vehicle (DMSO). On day 14 post-activation, cells were removed from culture, stained, and their exhaustion phenotype was analyzed via FACS. Representative plots from 3 independent experiments. FIG. 15A: CAR+ T cell canonical exhaustion marker expression.

**[0050]** FIG. 15B: CAR+ CD4+ (left) or CAR+ CD8+ (right) exhaustion marker co-expression. These results demonstrate that the HA-GD2.28z CAR tonically signals in the absence of antigen, which ultimately induces T cells exhaustion, as defined by expression of multiple inhibitory receptors, lack of memory formation, and decreased effector function. FIG. 14 demonstrates that expanding HA-GD2.28z CAR T cells in the presence of dasatinib dose-dependently attenuates exhaustion marker single expression (a) or co-expression (b).



**[0051]** FIG. 16: Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity to form memory. CD19.28z or HA-GD2.28z were expanded in the presence or absence of 1 uM dasatinib or vehicle (DMSO). On Day 14 post-activation, cells were removed from culture for FACS analysis. This representative plot shows CAR+ T cells. The red box highlights the CD45RA low, CCR7 high population, which corresponds to central memory-like T cells. These results demonstrate expanding tonically signaling HA-GD2.28z CAR T cells in dasatinib also augments memory formation, here demonstrated by a marked increase in the CD45RA low, CCR7 high population, which corresponds to a central memory-like phenotype.

**[0052]** FIG. 17: Tonically signaling CAR T cells expanded in the presence of dasatinib display augmented cytokine secretion in response to tumor antigen. HA-GD2.28z CAR T cells were expanded in the presence or absence of various concentrations of dasatinib or ponatinib. Drug was removed from the T cells 24 hours prior to co-culture with GD2-overexpressing nalm6 tumor cells in order to allow the T cells to regain the ability to signal in response to tumor. After 24 hours, supernatants were collected and IL-2 and IFN $\gamma$  secretion was assessed via ELISA. FIGS. 11, 12, 13, 15 and 16 demonstrate that dasatinib and ponatinib can inhibit CART cell signaling and function. FIG. 17 shows that expansion of tonically signaling HA-GD2.28z CART cells in the presence of these drugs followed by removal of the drugs prior to co-culturing with tumor cells results in augmentation of IL-2 and IFN $\gamma$ .

**[0053]** FIG. 18: Tonically signaling CART cells expanded in the presence of dasatinib display augmented cytotoxicity. HA-GD2.28z CAR T cells were expanded in the presence or absence of dasatinib or vehicle (DMSO) for 96 hours. On day 14 post-activation, dasatinib was removed from the T cells 24 hours prior to an incuocyte assay in which T cells were co-cultured at a 1:8 E:T ratio with GD2-overexpressing nalm6 tumor. Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point. These results demonstrate that inhibiting tonical signaling of HA-GD2.28z CAR T cells by including dasatinib in the culture medium during expansion followed by removal of dasatinib prior to co-culture rescues the ability of these CAR T cells to kill tumor.

**[0054]** FIG. 19: GD2-overexpressing Nalm6 in the presence and absence of dasatinib. 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice. On day 3 post-engraftment, 10E6 GD2.BBz CART cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The left plot displays the mean leg area $\pm$ SEM (n=5 mice). FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.

**[0055]** FIG. 20A: 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice. On day 3 post-engraftment, 10E6 HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The top plot displays the mean leg area $\pm$ SEM (n=5 mice). FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.

**[0056]** FIG. 20B: 1E6 GD2-overexpressing nalm6 tumor cells were engrafted intravenously in mice. On day 3 post-engraftment, 2E6 CAR+ HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The top plot displays the mean tumor luminescence $\pm$ SEM (n=5 mice). FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.

**[0057]** FIG. 21: 1E6 GD2-overexpressing nalm6 tumor cells were engrafted intravenously in mice. On day 3 post-engraftment, 2E6 HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. On day 17 post-engraftment, blood samples were taken from each mouse and mixed with counting beads. FACS analysis was performed, and the number of CD4+ and CD8+ cells for each mouse was calculated. This plot displays the mean CD4+ or CD8+ cells per mouse $\pm$ SEM (n=5 mice). FIG. 21 demonstrates one of the mechanisms by which dasatinib augments function. After infusing dasatinib-treated CAR T cells into mice, blood samples were taken and the number of circulating CAR T cells analyzed, a typical readout for in vivo CAR T cell proliferation in response to tumor. The vehicle HA-GD2.28z CAR T cells did not exhibit significantly more in vivo proliferation than mock T cells, as these cells were likely exhausted when they were initially infused into the mice. However, CAR T cells that were expanded in dasatinib retained their anti-tumor function and thus proliferated robustly in vivo.

**[0058]** FIG. 22A,B,C,D,E: In vivo dasatinib treatment suppresses exhaustion marker expression, augments memory formation, and facilitates cell survival/proliferation. Mice were engrafted with 1E6 GD2-overexpressing nalm6 tumor cells via intravenous injection. On day 4 post-engraftment, 2E6 HA-GD2.28z CAR T cells were infused into mice intravenously. Mice were dosed with 50 mg/kg dasatinib via intraperitoneal injection on days 21-23 post-tumor engraftment. 5 hours after dasatinib dosing on day 23, 1 mouse receiving vehicle and 1 mouse receiving dasatinib were sacrificed, and spleens/blood were harvested, surface stained, and phenotyped via FACS. A and C) CAR+ T cells constituted a higher percentage of total circulating cells (A) or total splenic cells (C) in the mouse treated with dasatinib versus the vehicle control. B and D) In contrast to mice treated with vehicle (red), circulating or splenic CD8+ CAR+ T cells in dasatinib-treated mice (blue) exhibited a phenotype consistent with a non-activated or resting T cell, indicating that dasatinib suppressed CAR T cell activation and induced memory formation (i.e., higher CD62L expression) in vivo. E) On days 27-29 post-tumor engraftment, 1 mouse received 50 mg/kg dasatinib each day and a different mouse received vehicle control. On days 30-32, mice were untreated. On day 32, tumor luminescence was assessed. The 3 days of dasatinib dosing were sufficient to induce a robust reinvigoration of the anti-tumor response (blue). These data indicate that iterative dosing of dasatinib may reinvigorate exhausted T cells in vivo.

**[0059]** FIG. 23: The nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv).

**[0060]** FIG. 24: The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv).



**[0061]** FIG. 25: The nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv).

**[0062]** FIG. 26: The nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv).

#### DEFINITIONS

**[0063]** It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a T cell” includes two or more T cells, and the like.

**[0064]** The term “about,” particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.

**[0065]** The term “chimeric antigen receptor” or “CAR,” as used herein, refers to an artificial T cell receptor that is engineered to be expressed on an immune effector cell and specifically bind an antigen. CARs may be used as a therapy with adoptive cell transfer. T cells are removed from a patient and modified so that they express the receptors specific to a particular form of antigen. In some embodiments, the CARs have been expressed with specificity to a tumor associated antigen, for example. CARs may also comprise an intracellular activation domain, a transmembrane domain and an extracellular domain comprising a tumor associated antigen binding region. The specificity of CAR designs may be derived from ligands of receptors (e.g., peptides). In some embodiments, a CAR can target cancers by redirecting the specificity of a T cell expressing the CAR specific for tumor associated antigens.

**[0066]** “Pharmaceutically acceptable excipient or carrier” refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.

**[0067]** “Pharmaceutically acceptable salt” includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).

**[0068]** The term “T cell” refers to T lymphocytes as defined in the art and is intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. The T cells can be CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup>CD8<sup>+</sup> T cells, or CD4<sup>+</sup>CD8<sup>+</sup> cells. The T cells can also be T helper cells, such as T helper 1 (TH1), or T helper 2 (TH2) cells, or TH17 cells, as well as cytotoxic T cells, regulatory T cells, natural killer T cells, naïve T cells, memory T cells, or gamma delta T cells.

**[0069]** The T cells can be a purified population of T cells, or alternatively the T cells can be in a population with cells of a different type, such as B cells and/or other peripheral blood cells. The T cells can be a purified population of a subset of T cells, such as CD4<sup>+</sup> T cells, or they can be a population of T cells comprising different subsets of T cells.

In another embodiment of the invention, the T cells are T cell clones that have been maintained in culture for extended periods of time. T cell clones can be transformed to different degrees. In a specific embodiment, the T cells are a T cell clone that proliferates indefinitely in culture.

**[0070]** In some embodiments, the T cells are primary T cells. The term “primary T cells” is intended to include T cells obtained from an individual, as opposed to T cells that have been maintained in culture for extended periods of time. Thus, primary T cells are particularly peripheral blood T cells obtained from a subject. A population of primary T cells can be composed of mostly one subset of T cells. Alternatively, the population of primary T cells can be composed of different subsets of T cells.

**[0071]** The T cells can be from previously stored blood samples, from a healthy individual, or alternatively from an individual affected with a condition. The condition can be an infectious disease, such as a condition resulting from a viral infection, a bacterial infection or an infection by any other microorganism, or a hyperproliferative disease, such as cancer like melanoma. In yet another embodiment of the invention, the T cells are from a subject suffering from or susceptible to an autoimmune disease or T-cell pathologies. The T cells can be of human origin, murine origin or any other mammalian species.

**[0072]** “T cell exhaustion” refers to loss of T cell function, which may occur as a result of an infection or a disease. T cell exhaustion is associated with increased expression of PD-1, TIM-3, and LAG-3, apoptosis, and reduced cytokine secretion.

**[0073]** By “therapeutically effective dose or amount” of an inhibitor of TCR signaling (e.g., dasatinib) is intended an amount that, when administered as described herein, brings about a positive therapeutic response in treatment of T cell exhaustion, such as restored T cell function. Improved T cell function may include decreased expression of PD-1, TIM-3, and LAG-3, maintenance of memory markers (e.g., CD62L or CCR7), prevention of apoptosis, and increased secretion of IL-2 and other cytokines. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.

**[0074]** The terms “subject,” “individual,” and “patient,” are used interchangeably herein and refer to any vertebrate subject, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.

#### DETAILED DESCRIPTION OF THE INVENTION

**[0075]** The invention is based on the discovery that transient inhibition or modulation of TCR signaling and/or CAR



signaling in human T cells can prevent or reverse T cell exhaustion and restore T cell function. The inventors have shown that GD2-CAR expressing T cells develop functional exhaustion, exhibited by expression of PD-1, TIM-3, and LAG-3 exhaustion markers. Cessation of tonic signaling restores the ability of T cells to secrete IL-2 in response to tumor antigen. The inventors further showed that treatment with dasatinib, a Lck tyrosine kinase inhibitor that inhibits T cell receptor signaling, reduced expression of the T cell exhaustion markers and improved preservation of T cell memory.

**[0076]** Protein tyrosine kinases are a family of enzymes catalysing the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Phosphorylation of tyrosine residues on protein substrates leads to transduction of intracellular signals which regulate a wide variety of intracellular processes such as growth and activation of cells of the immune system, e.g. T-cells. As T-cell activation is implicated in a number of inflammatory conditions and other disorders of the immune system (e.g. autoimmune diseases), modulation of the activity of protein tyrosine kinases appears to be an attractive route to the management of inflammatory diseases. A large number of protein tyrosine kinases have been identified which may be receptor protein tyrosine kinases, e.g. the insulin receptor, or non-receptor protein tyrosine kinases.

**[0077]** Protein tyrosine kinases of the Src family have been found to be particularly important for intracellular signal transduction related to inflammatory responses (see, e.g., D. Okutani et al., *Am. J. Physiol. Lung Cell Mol. Physiol.* 291, 2006, pp. L129-L141; CA. Lowell, *Mol. Immunol.* 41, 2004, pp. 631-643). While some of Src family protein tyrosine kinases, e.g. Src, Yes and Fyn, are expressed in a variety of cell types and tissues, the expression of others is restricted to specific cell types, e.g. hematopoietic cells. Thus, the protein tyrosine kinase Lck is expressed almost exclusively in T-cells as the first signalling molecule to be activated downstream of the T-cell receptor, and its activity is essential for T-cell signal transduction. Expression of Hck, Lyn and Fgr is increased by inflammatory stimuli such as LPS in mature monocytes and macrophages. Also, if gene expression of the main B-cell Src family kinases, namely Lyn, Fyn and Blk, is disrupted, immature B-cells are prevented from developing into mature B-cells. Src family kinases have also been identified as essential for the recruitment and activation of monocytes, macrophages and neutrophils as well as being involved in the inflammatory response of tissue cells.

**[0078]** As noted, receptor tyrosine kinases are essential components of signal transduction pathways that mediate cell-to-cell communication and their function as relay points for signaling pathways. They have a key role in numerous processes that control cellular proliferation and differentiation, regulate cell growth and cellular metabolism, and promote cell survival and apoptosis. Lck (p56<sup>lck</sup> or lymphocyte specific kinase) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T cell receptor (TCR)-mediated signaling, leading to normal T-cell development and activation. As such, selective inhibition of Lck is useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection.

**[0079]** The invention is further based on the discovery that the Lck kinase inhibitor dasatinib and the receptor tyrosine kinase inhibitor ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies). First, these drugs were shown to potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible. Second, expansion of CAR T cells in the presence of dasatinib or ponatinib was shown to prevent CAR tonic signaling and in turn enhance the functional capacity of CAR T cells. Lastly, providing short periods of CAR T cell “rest” in vivo via iterative drug dosing was shown to be one method by which CAR T cell exhaustion could be prevented or reversed and/or memory could be induced.

**[0080]** Accordingly, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).

**[0081]** As such, the present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations to compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population. Indeed, the present invention contemplates that the use of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) within adoptive T cell therapies satisfies an unmet need as the effectiveness of such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion. Thus, the present invention provides methods for treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells and particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0082]** Such tyrosine kinase inhibitors may be administered by any suitable mode of administration, but is typically administered orally. Multiple cycles of treatment may be



administered to a subject. In certain embodiments, the tyrosine kinase inhibitors are administered according to a daily dosing regimen or intermittently. In another embodiment, the tyrosine kinase inhibitors are administered for a period of time sufficient to restore at least partial T cell function, then discontinued.

**[0083]** The present invention contemplates that ex vivo expansion of a population of T cells with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in a population T cells that are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides compositions comprising a population of T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors). Thus, the present invention provides methods of expanding a population of T cells to generate T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides kits comprising T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and additional agents (e.g., additional agents useful in expanding T cells) (e.g., additional agents useful in adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0084]** The present invention contemplates that ex vivo expansion of a population of genetically engineered T cells (e.g., genetically engineered for use within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy)) with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) will result in genetically engineered T cells that are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides compositions comprising a population of genetically engineered T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides methods of expanding a population of genetically engineered T cells to generate genetically engineered T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides kits comprising genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL)

therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0085]** The present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides methods of treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering a population of genetically engineered T cells expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0086]** Such embodiments are not limited to a particular type or kind of an immune system related condition or disease.

**[0087]** For example, in some embodiments, the immune system related condition or disease is an autoimmune disease or condition (e.g., Acquired Immunodeficiency Syndrome (AIDS), alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, cardiomyopathy, celiac sprue-dermatitis hepeticiformis; chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricial pemphigoid, cold agglutinin disease, crest syndrome, Crohn's disease, Degos' disease, dermatomyositis-juvenile, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin-dependent diabetes mellitus, juvenile chronic arthritis (Still's disease), juvenile rheumatoid arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomena, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma (progressive systemic sclerosis (PSS), also known as systemic sclerosis (SS)), Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vitiligo, Wegener's granulomatosis, and any combination thereof).


**[0088]** For example, in some embodiments, the immune system related condition or disease is cancer (e.g., breast




cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and thyroid carcinoma).

**[0089]** The present invention contemplates that the use of genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) satisfies an unmet need as such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion. Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**[0090]** The embodiments of the present invention are not limited to specific types of tyrosine kinase inhibitors. In some embodiments, the tyrosine kinase inhibitors are a Lck tyrosine kinase inhibitors. In some embodiments, the tyrosine kinase inhibitor is a Src family kinase inhibitor (e.g., Src kinase inhibitor, Yes kinase inhibitor, Fyn kinase inhibitor, Fgr kinase inhibitor, Lck kinase inhibitor, Hck kinase inhibitor, Blk kinase inhibitor, Lyn kinase inhibitor). In some embodiments, the tyrosine kinase inhibitor is dasatinib



(N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide), or a pharmaceutically acceptable salt, solvate, or prodrug thereof. In some embodiments, the tyrosine kinase inhibitor is ponatinib



(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide), or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

**[0091]** Some embodiments of the present invention provide for administering such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and

compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) in combination with an effective amount of at least one additional therapeutic agent (including, but not limited to, chemotherapeutic anti-neoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiotherapies). In a particular embodiment, the additional therapeutic agent(s) is an anticancer agent.

**[0092]** Tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients. Exemplary excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof. Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants. A carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient. Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like. The excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof.

**[0093]** A surfactant can be present as an excipient. Exemplary surfactants include: polysorbates, such as "Tween 20" and "Tween 80," and pluronics such as F68 and F88 (BASF, Mount Olive, N.J.); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations.

**[0094]** Acids or bases can be present as an excipient in the pharmaceutical composition. Nonlimiting examples of acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof. Examples of suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumarate, and combinations thereof.

**[0095]** The amount of the tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) (e.g., when contained in a drug delivery system) in the pharmaceutical composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial). A therapeutically



effective dose can be determined experimentally by repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.

**[0096]** The amount of any individual excipient in the pharmaceutical composition will vary depending on the nature and function of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred. These foregoing pharmaceutical excipients along with other excipients are described in “Remington: The Science & Practice of Pharmacy”, 19<sup>th</sup> ed., Williams & Williams, (1995), the “Physician’s Desk Reference”, 52<sup>nd</sup> ed., Medical Economics, Montvale, N.J. (1998), and Kibbe, A. H., Handbook of Pharmaceutical Excipients, 3<sup>rd</sup> Edition, American Pharmaceutical Association, Washington, D.C., 2000.

**[0097]** The pharmaceutical compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration. Examples of suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate buffered saline, Ringer’s solution, saline, sterile water, deionized water, and combinations thereof. With respect to liquid pharmaceutical compositions, solutions and suspensions are envisioned. Additional preferred compositions include those for oral, ocular, or localized delivery.

**[0098]** The pharmaceutical preparations herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use. Preferably, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) described herein are in unit dosage form, meaning an amount of a conjugate or composition of the invention appropriate for a single dose, in a premeasured or pre-packaged form.

**[0099]** The pharmaceutical compositions herein may optionally include one or more additional agents, or may be combined with one or more additional agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies). Compounded preparations may be used including at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and one or more other agents, such as other drugs for treating T cell exhaustion or an infection or disease associated with T cell exhaustion. Alternatively, such agents can be contained in a separate composition from the composition

comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and co-administered concurrently, before, or after the composition comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib).

**[0100]** At least one therapeutically effective cycle of treatment with a tyrosine kinase inhibitor (e.g., a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib)) will be administered to a subject for treatment of T cell exhaustion. By “therapeutically effective cycle of treatment” is intended a cycle of treatment that when administered, brings about a positive therapeutic response with respect to treatment of an individual for T cell exhaustion. Of particular interest is a cycle of treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) that, when administered transiently as described herein, restores T cell function. For example, a therapeutically effective dose or amount of a tyrosine kinase inhibitor may decrease expression of PD-1, TIM-3, and LAG-3, improve maintenance of memory markers (e.g., CD62L or CCR7), prevent apoptosis, and increase secretion of IL-2 and other cytokines.

**[0101]** In certain embodiments, multiple therapeutically effective doses of pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and/or one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies) will be administered. The pharmaceutical compositions of the present invention are typically, although not necessarily, administered orally, via injection (subcutaneously, intravenously, or intramuscularly), by infusion, or locally. Additional modes of administration are also contemplated, such as topical, intralesion, intracerebral, intracerebroventricular, intraparenchymatous, pulmonary, rectal, transdermal, transmucosal, intrathecal, pericardial, intra-arterial, intraocular, intraperitoneal, and so forth.

**[0102]** The pharmaceutical preparation can be in the form of a liquid solution or suspension immediately prior to administration, but may also take another form such as a syrup, cream, ointment, tablet, capsule, powder, gel, matrix, suppository, or the like. The pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and other agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.

**[0103]** In another embodiment, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and/or other agents are administered prophylactically, e.g., to prevent T cell exhaustion. Such prophylactic uses will be of particular value for subjects with a chronic infection or cancer, who are at risk of developing T cell exhaustion.

**[0104]** In another embodiment of the invention, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and/or other agents are in a sustained-release formulation, or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to



achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.

**[0105]** The invention also provides a method for administering a conjugate comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) as provided herein to a patient suffering from a condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) contained in the conjugate or composition. The method comprises administering, via any of the herein described modes, a therapeutically effective amount of the conjugate or drug delivery system, preferably provided as part of a pharmaceutical composition. The method of administering may be used to treat any condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib). More specifically, the pharmaceutical compositions herein are effective in treating T cell exhaustion.

**[0106]** Those of ordinary skill in the art will appreciate which conditions a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) can effectively treat. The actual dose to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered. Therapeutically effective amounts can be determined by those skilled in the art, and will be adjusted to the particular requirements of each particular case.

**[0107]** Generally, a therapeutically effective amount will range from about 0.50 mg to 5 grams of a tyrosine kinase inhibitor daily, more preferably from about 5 mg to 2 grams daily, even more preferably from about 7 mg to 1.5 grams daily. Preferably, such doses are in the range of 10-600 mg four times a day (QID), 200-500 mg QID, 25-600 mg three times a day (TID), 25-50 mg TID, 50-100 mg TID, 50-200 mg TID, 300-600 mg TID, 200-400 mg TID, 200-600 mg TID, 100 to 700 mg twice daily (BID), 100-600 mg BID, 200-500 mg BID, or 200-300 mg BID. The amount of compound administered will depend on the potency of the tyrosine kinase inhibitor and the magnitude or effect desired and the route of administration.

**[0108]** A purified tyrosine kinase inhibitor (again, preferably provided as part of a pharmaceutical preparation) can be administered alone or in combination with one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs); or adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy); or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth. The specific dosing schedule will be known by those of ordinary skill in the art or can be determined experimentally using routine methods. Exemplary dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof. Preferred compositions are those requiring dosing no more than once a day.

**[0109]** A tyrosine kinase inhibitor can be administered prior to, concurrent with, or subsequent to other agents or therapies. If provided at the same time as other agents or

therapies, one or tyrosine kinase inhibitors can be provided in the same or in a different composition. Thus, one or more tyrosine kinase inhibitors and other agents can be presented to the individual by way of concurrent therapy. By “concurrent therapy” is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering a dose of a pharmaceutical composition comprising a tyrosine kinase inhibitor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating T cell exhaustion, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen. Similarly, one or more tyrosine kinase inhibitors and one or more other therapeutic agents can be administered in at least one therapeutic dose. Administration of the separate pharmaceutical compositions or therapies can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.

**[0110]** The invention also provides kits comprising one or more containers holding compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and optionally one or more other agents for treating T cell exhaustion. Compositions can be in liquid form or can be lyophilized. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).

**[0111]** The kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer’s solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices. The delivery device may be pre-filled with the compositions.

**[0112]** The kit can also comprise a package insert containing written instructions for methods of using the compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) for treating a subject for T cell exhaustion. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.

**[0113]** One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the compositions and methods described above can readily be achieved using expertise available in the art and are within the scope of the invention.

## EXAMPLES

**[0114]** The following examples are illustrative, but not limiting, of the compounds, compositions, and methods of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters



normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

### Example I. A Method of Preventing or Reversing T Cell Exhaustion by Inhibiting or Modulating TCR Signaling

#### Introduction

**[0115]** We previously reported that GD2-CAR expressing T cells develop functional exhaustion within 10 days in culture and are characterized by co-expression of inhibitory receptors, failure to secrete cytokines in response to tumor antigen, and aberrant metabolic function (Long et. al, Nat Med 2015). Control cultures included untransduced T cells (mock) and those expressing CD19-CAR, which does not manifest tonic signaling or develop exhaustion in vitro. Previous work also demonstrated that the zeta chain was required for exhaustion in this system, with CD28 signaling enhancing the potency of the signaling stimulus in inducing exhaustion. Using this model system, we have now optimized a robust, manipulatable, and reproducible in vitro human model of T cell exhaustion to evaluate approaches to prevent or reverse T cell exhaustion.

#### Results

**[0116]** We engineered a GD2.28z CAR fused to an FKBP12 mutant destabilization domain (Banaszynski et. al, Cell 2006) (GD2.28z.FKBP) which confers its instability to the CAR and induces rapid protein degradation. We observed that surface expression could be rapidly and dose-dependently regulated by adding or subtracting the stabilizing rapalog shield-1 (S1) in culture medium (FIG. 1). Similar regulatability of CAR expression was also accomplished using an *E. coli* DHFR mutant (GD2.28z.DHFR, not shown), which could be regulated by trimethoprim, an antibiotic that is commonly used clinically.

**[0117]** Since tonic signaling is highly dependent upon GD2-CAR receptor levels, precise control of CAR expression levels also precisely regulates levels of tonic signaling. Drug regulated control of levels of CAR expression therefore also allowed modulation of the duration and intensity of GD2.28z tonic signaling. Using this system, we demonstrated that phenotypic and functional changes associated with exhaustion were reversed upon cessation of CAR signaling. As shown in FIG. 2, removal of S1 drug from the culture medium and consequent removal of surface CAR on day 7 post-activation reverses canonical exhaustion marker expression to control levels by day 10 (FIG. 2, n=3). This is most well illustrated by measuring levels of PD-1/TIM-3/LAG-3 triple expressing cell which is highly specific for dysfunctional, exhausted T cells. We demonstrate that Day 10 clear induces increases in levels of triple expressing exhausted cells, but that removal of S1 on Day 7 results in normalization of these levels by Day 10. Similar results were obtained on day 14 for cells in which S1 was removed from culture medium on day 7 or day 10 (not shown).

**[0118]** Additionally, removal of S1 on day 7 or 10, allow transient degradation of CAR proteins results in maintenance of memory markers (ex. CD62L) and prevention of apoptosis (i.e., annexin V staining) by day 14 compared to T cells that received S1 for the entire duration of the culture (S1) (FIG. 3).

**[0119]** Because phenotypic markers may not be entirely predictive of T cell function, we also performed functional experiments on CAR T cells provided transient drug exposure in culture. CAR T cells were washed, resuspended in media containing S1, and mixed at a 1:1 ratio with Nalm6 leukemic cells stably expressing surface GD2. Culture supernatants were harvested approximately 24 hours later and cytokine levels were evaluated via ELISA. Similar to GD2.28z CAR that lacks a destabilization domain and therefore have persistent high levels of CAR signaling, cells expressing the GD2.28z.FKBP CAR that experienced continuous drug treatment (FIG. 4, grey bars) secreted minimal amounts of IL-2 on both day 10 and day 14 post-activation, consistent with T cell exhaustion. Alternatively, CART cells that were not exposed to drug during culture (black bars) and therefore did not experience tonic signaling demonstrated significant bioactivity as measured by IL-2 production. Finally, CAR T cells that were exposed to drug during the initial 7 or 10 days of culture and therefore acquired phenotypic and functional evidence of T cell exhaustion, but had drug removed from the culture medium on day 7 or day 10 (blue and red bars, respectively) displayed a restored capacity to secrete IL-2 in response to tumor antigen. Remarkably, exhausted T cells on day 10 (grey bar, day 10 ELISA) could be reinvigorated by removing S1 from the culture medium and “rested” for only 4 days (red bar, day 14 ELISA). Similar, but less dramatic augmentation of IFN $\gamma$  secretion in conditions in which S1 was removed from culture medium was also observed. These functional data cannot be attributed to differential CAR surface expression, as all groups exhibited similar levels of surface CAR at the conclusion of this co-culture assay (not shown).

**[0120]** We then compared whether prevention or reversal of T cell exhaustion by removal of surface CAR was more or less potent than treatment with well-characterized anti-PD-1 checkpoint inhibitor, nivolumab (Nivo). CART cells were either treated with continuous S1 (and thus exhibit continuous tonic signaling), continuous S1+nivolumab, or no S1 until the time of the co-culture assay. Interestingly, nivolumab treatment resulted in only modest augmentation of IL-2 secretion at day 10, which was sustained until day 14, suggesting that nivolumab only partially prevented the onset of T cell exhaustion in this system (FIG. 5). Conversely, culturing CART cells without S1, then adding it back to the medium just prior to the co-culture assay (left chart, blue bars), resulted in a far superior prevention of exhaustion, as IL-2 secretion was augmented 5-10 fold compared to CART cells that experienced continuous S1 (black bars). Further, removing tonic signaling on day 7 by removing S1 from the culture medium also resulted in superior IL-2 secretion compared to CAR T cells that experienced continuous S1, and those that experienced continuous S1 and were simultaneously treated with S1. Collectively, these data demonstrate that modulating tonic signaling exhibits more potent effects on prevention or reversal of exhaustion compared to PD-1 blockade.

**[0121]** Functional studies by several groups, including our lab have verified that co-expression of PD-1, TIM-3, and LAG-3 (triple positive, TP) denotes an exhausted cell subset that is highly dysfunctional. We thus sought to analyze whether cessation of tonic signaling in this cell subset could reverse their phenotype and restore their ability to secrete IL-2 in response to tumor antigen. A high affinity version of our GD2.28z CAR (HA-GD2.28z), which exhibits an even



more dramatic exhausted phenotype, was fused to the FKBP12 mutant destabilization domain in order to control its surface expression. On day 10 post-activation, HA-GD2.28z.FKBP CAR T cells that had experienced continuous S1 treatment were sorted in order to isolate a pure PD-1/TIM-3/LAG-3 exhausted population. “Triple positive” exhausted cells were then re-cultured either with or without S1 to test whether removal of tonic signaling could restore their function. FACS and co-culture assays were conducted 4 days later.

**[0122]** Removal of S1 resulted in a dramatic reversal of the exhausted phenotype. After only 4 days without S1 in the medium, pre-sorted triple positive cells exhibited far less expression of exhaustion markers in both CD4+ and CD8+ CAR T cells (FIG. 6). Importantly, these phenotypic changes also conferred functional augmentation in IL-2 secretion, as removal of S1 resulted in a 2-fold increase in IL-2 secretion compared to triple positive cells that received continuous S1 treatment from days 10-14 (FIG. 6).

**[0123]** We hypothesized that we could recapitulate the effects of removing surface CAR, and thus tonic signaling, by simply inhibiting kinases in the TCR signaling pathway that are also integral to CAR signaling. One such kinase is Lck, which acts to phosphorylate CD3 zeta in response to TCR or CAR ligation. Dasatinib, a potent receptor tyrosine kinase inhibitor and BCR/ABL antagonist, has also been shown to inhibit T cell activation, proliferation, and cytokine secretion by binding to and inhibiting Lck at low concentrations (Schade et. al, Blood, 2008 and Lee et. al, Leukemia, 2010).

**[0124]** At 100 nM and 1  $\mu$ M concentrations, dasatinib potently inhibits CD19.28z CART cell cytokine secretion in response to tumor antigen on day 14 post-activation (FIG. 7), proving that dasatinib disrupts CAR signaling.

**[0125]** We then asked whether transient dasatinib exposure could reverse T cell exhaustion by treating HA-GD2.28z CART cells with dasatinib on days 10-14 post-activation. Cells were treated with dasatinib for 4 days, then drug was extensively washed from the media, and cells were re-cultured for an additional 24 hours before examining their phenotype and function via FACS and tumor co-culture assays. Interestingly, 4-day treatment with dasatinib reversed exhaustion marker expression and co-expression in a dose-dependent manner (FIG. 8).

**[0126]** Furthermore, dasatinib treatment resulted in preservation of T cell memory via maintenance of CD62L expression in a dose-dependent manner (FIG. 9.).

**[0127]** Finally, similar to removal of surface CAR, dasatinib treatment reinvigorated exhausted T cells in a functionally significant manner, as dasatinib-treated CAR T cells secreted more IL-2 (and to a lesser extent, IFN $\gamma$ ) in response to tumor antigen compared to those that never received dasatinib (FIG. 10).

**[0128]** Collectively, these data demonstrate that selective inhibition or modulation of TCR signaling can substantially enhance the function of exhausted T cells that experience continuous antigen exposure in the context of cancer or chronic infection. In future studies, we will conduct in vivo studies to assess the feasibility of exhaustion reversal in this setting and whether such reversal can enhance antitumor effects in murine models.

## Example II

**[0129]** Chimeric antigen receptors (CARs) are synthetic receptors that combine an extracellular tumor-targeting domain with intracellular domains that mimic endogenous TCR signaling (e.g., 1-2 costimulatory domains, like CD28 or 4-1BB, and a CD3 zeta domain) (see, e.g., Lim & June. Cell 168, 724-740 (2017)). When CAR-expressing T cells encounter antigen-expressing tumor cells, CAR T cells form an immune synapse and initiate downstream signaling through the CAR, resulting in potent T cell activation, degranulation of cytotoxic soluble factors, cytokine release, and proliferation. While CAR T cell therapy has experienced unprecedented clinical success in many patients with hematological malignancies, there are several key challenges that must be addressed before this therapy can be expanded to other tumor types or offered as first-line therapy.

**[0130]** One challenge is CAR toxicity, which typically manifests in the form of cytokine release syndrome (CRS) or on-target off-tumor activity, both of which have been observed in clinical trials and, in some instances, resulted in patient death (see, e.g., Gust et al. Cancer discovery (2017). doi:10.1158/2159-8290.cd-17-0698; Xu & Tang. Cancer Letters 343, 172-178 (2014); D’Aloia, et al. Cell Death & Disease 9, 282 (2018)). Current methods to counteract CAR toxicity are largely limited to a drug-inducible suicide switches (i.e., inducible Caspase 9) that mediate CAR T cell apoptosis (see, e.g., Gargett & Brown. Frontiers in Pharmacology 5, 235 (2014)). While generally regarded as an effective safety mechanism, utilizing this method eliminates the option to continue therapy after the toxicity event resolves, as the CAR T cells are no longer viable.

**[0131]** A second key challenge to improving the efficacy of CAR T cell therapy is the prevention of CAR T cell exhaustion. T cell exhaustion results from continuous antigen exposure in the context of chronic viral infection or cancer and is characterized by a hierarchical loss of effector function, sustained co-expression of multiple inhibitory receptors (ex., PD-1, TIM-3, LAG-3), attenuated proliferative capacity, and increase apoptosis (see, e.g., Wherry & Kurachi. Nature Reviews Immunology 15, nri3862 (2015)). There is strong evidence for T cell exhaustion in CART cell therapy. Nearly all CD19.28z CART cells administered disappear by day 60 post-infusion (see, e.g., Lee et al. Long-term outcomes following CD19 CART cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. (2016)). CD19.BBz CART cells, which are thought to be more resistant to T cell exhaustion, also exhibit features of exhaustion and are undetectable in approximately 30% of patients who receive this therapy, consequently increasing the risk of CD19 positive relapse (see, e.g., Turtle et al. Journal of Clinical Investigation 126, 2123-2138 (2016); Maude et al. The New England Journal of Medicine 371, 1507-1517 (2014)). Lastly, exhaustion has also been observed in T cells constitutively expressing CARs that manifest scFv aggregation-induced tonic signaling, which occurs both in the absence of tumor antigen. This unintended consequence of high CAR expression ultimately limits their effectiveness by exhausting CART cells in vitro and in vivo (see, e.g., Long et al. Nature Medicine 21, 581-590 (2015); Gomes-Silva et al. Cell Reports 21, 17-26 (2017)).

**[0132]** Experiments conducted during the course of developing embodiments for the present invention addressed both



of these challenges by utilizing FDA-approved small molecule tyrosine kinase inhibitors to modulate CAR T cell activity. Several BCR-Abl inhibitors have been shown to have cross-reactivity with signaling kinases required for T cell activation (see, e.g., Banaszynski, et al. *Nature medicine* 14, 1123-7 (2008); Banaszynski, et al. *Cell* 126, 995-1004 (2006); Iwamoto, et al. *Chemistry & Biology* 17, 981-988 (2010)). Dasatinib potently inhibits T cell activation and effector functions by inhibiting both Lck and Fyn. Similarly, ponatinib can bind to and inhibit Lck, but does not affect the function of Fyn or Src kinases, suggesting that this drug can also inhibit T cell effector function, and likewise, CAR T cell function.

**[0133]** To test this hypothesis, T cells expressing the CD19-targeting CAR (CD19.28z) were incubated with various concentrations of dasatinib and ponatinib for at least 24 hours. CAR T cells were next co-cultured with antigen-bearing tumor cells for 6 hours in the presence or absence of dasatinib/ponatinib, and subsequently assessed CAR T cell activation and degranulation via CD69 and CD107a co-expression. Nearly 80% of control CART cells were CD69+/CD107a+ upon co-culture with tumor (FIG. 11a). Conversely, nanomolar levels of dasatinib and ponatinib potently inhibited activation and degranulation of CAR T cells in a dose-dependent manner (FIG. 11b). These drugs also potently inhibited CAR T cell IL-2 and IFN $\gamma$  secretion in response to tumor (FIG. 12). Finally, we observed potent inhibition of CAR T cell cytotoxicity when CAR T cells were co-cultured with tumor cells in the presence of 1  $\mu$ M dasatinib (FIG. 13).

**[0134]** To assess whether dasatinib was inhibiting CAR T cell effector function by disrupting CAR signaling, experiments were conducted in which surface CAR were transiently crosslinked on CAR T cells in order to transiently initiate CAR downstream signaling. Under control conditions, cross-linking CAR for 5 minutes induced phosphorylation of the CAR CD3 zeta domain, as well as phosphorylation of distal signaling kinases Akt and Erk1/2 (FIG. 14). Conversely, when CAR T cells were crosslinked in the presence of dasatinib, they resembled non-crosslinked controls, indicating that dasatinib potently disrupted CAR-specific intracellular signaling. Collectively, these experiments indicate that both dasatinib and ponatinib inhibit CAR T cell activity and provide indirect evidence that Lck and/or Fyn are critical for CAR signaling. These experiments also indicate that dasatinib or ponatinib could be utilized clinically to disrupt CAR T cell activity in order to mitigate CAR T cell toxicity.

**[0135]** As previously mentioned, many constitutively expressed CARs exhibit tonic signaling in the absence of antigen during in vitro expansion, consequently driving them towards T cell exhaustion (see, e.g., Long et al. *Nature Medicine* 21, 581-590 (2015)). Additional experiments hypothesized that expanding CART cells in the presence of dasatinib or ponatinib would alleviate tonic signaling and consequently yield a healthier, more potent CAR T cell. To test this, T cells expressing a tonically signaling, high-affinity GD2.28z CAR (HA-GD2.28z) were expanded in the presence of various concentrations of dasatinib. Cells were then removed from culture for phenotypic analysis via FACS. Control HA-GD2.28z CART cells exhibited robust single marker expression and co-expression of multiple canonical exhaustion markers (FIG. 15). Conversely, expansion in dasatinib reduced both the frequency of exhaustion-

marker co-expressing cells as well as the extent to which these exhaustion markers were expressed in a dose-dependent manner (FIG. 15). CART cell expansion in the presence of dasatinib also augmented T cell memory formation, as a nearly 6-fold increase in the frequency of central-memory-like T cells (CD45RA low, CCR7 high) and a greater-than 2-fold reduction in the frequency of effector-memory-like T cells (CD45RA low, CCR7 low) was observed compared to exhausted CAR T cells cultured in the absence of dasatinib.

**[0136]** Experiments next hypothesized that the dramatic phenotypic changes observed when tonic signaling was mitigated by dasatinib or ponatinib may coincide with an augmentation in T cell function. To test this, experiments first expanded tonically signaling CAR T cells in the presence or absence of various concentrations of dasatinib or ponatinib. Experiments next removed the drugs from culture in order to allow CAR T cells to regain the capacity to function. 18-24 hours after removal of drug, the differentially expanded CAR T cells were co-cultured with antigen-bearing tumor cells for 24 hours and subsequently assessed cytokine release via ELISA, or co-cultured for 72 hours and assessed cytotoxicity via incucyte assay. Tonically signaling CAR T cells cultured in the absence of dasatinib or ponatinib secreted low levels of cytokine in response to tumor (FIG. 17) and exhibited impaired cytotoxicity (FIG. 18), indicating that these cells were functionally exhausted. Alternatively, expansion of CAR T cells in the presence of dasatinib or ponatinib dose-dependently augmented CAR T cell cytokine secretion (FIG. 17) and also allowed for a more potent cytotoxic response (FIG. 18), confirming that the mitigation of tonic signaling during CAR T cell expansion with these drugs confers profound functional benefits.

**[0137]** Experiments were conducted that tested whether prevention of CAR tonic signaling in vitro augmented the anti-tumor response in vivo. CAR T cells were expanded with or without 1  $\mu$ M dasatinib and subsequently infused into NSG mice engrafted with antigen-bearing tumor. In a solid tumor model using the 143B osteosarcoma cell line, both GD2.BBz and HA-GD2.28z CAR T cells grown in the absence of dasatinib failed to control tumor growth (FIGS. 19 and 20, respectively). However, CAR T cells expanded in dasatinib allowed for a near complete and lasting eradication of the tumor (FIGS. 19 and 20). The same effect was observed in a GD2-overexpressing NALM6 leukemia model in which the tumor burden was more established at the time of CART cell infusion (FIG. 21).

**[0138]** Experiments were next conducted to determine whether greater CAR T cell proliferation and/or persistence were a few of the key mechanisms by which in vitro expansion in dasatinib augments the anti-tumor response. To test this, CAR T cells were infused into mice that had been engrafted with antigen-bearing tumor. On day 14 post-infusion, blood samples were taken from the mice and the number of circulating CAR T cells was assessed via FACS counting beads. Tonically signaling HA-GD2.28z CAR T cells expanded in the absence of dasatinib did not expand and/or persist at levels greater than mice infused with mock untransduced T cells (FIG. 22). Conversely, both CD4+ and CD8+ CAR T cells that were grown in the presence of 1  $\mu$ M dasatinib underwent a profound expansion in vivo and persisted (FIG. 22). Collectively, these data indicate that limiting CAR tonic signaling by expanding CAR T cells in



dasatinib in vitro augments the in vivo anti-tumor response by increasing the capacity for CAR T cells to expand and persist.

**[0139]** Experiments were next conducted that questioned whether in vivo administration of dasatinib could alter CAR T cell phenotype and function. As a proof-of-concept experiment, CAR T cells were infused into mice that were engrafted with antigen-bearing tumor and subsequently dosed with dasatinib for 3 consecutive days. The mice were then sacrificed and CAR T cell frequency and phenotype assessed in both the blood and the spleen. The dasatinib-treated mouse exhibited a higher frequency of CAR T cells in both tissues (FIG. 22a, c) compared to the vehicle-treated mouse, indicating that in vivo dasatinib treatment induced in situ proliferation or persistence. Furthermore, CAR T cells that were recovered from the dasatinib-treated mouse exhibited reduced expression of exhaustion markers PD-1 and LAG-3, reduced expression of CD69 (i.e. lower activation state), and higher expression of the memory marker CD62L (FIG. 22b, d) compared to the vehicle-treated mouse, all of which are consistent with the phenotypic changes observed upon in vitro treatment with dasatinib (FIG. 15, 16). These results demonstrate that in vivo administration of dasatinib mitigates CAR T cell exhaustion phenotype and improves memory formation, and indicates that in vivo dasatinib dosing provides a functional benefit in vivo.

**[0140]** Experiments hypothesized that selective in vivo administration of dasatinib will prevent CAR T cell exhaustion by transiently “resting” CAR T cells that are experiencing chronic antigen stimulation. To test this, CAR T cells were infused into mice that exhibited high tumor burden. On day 27 post-tumor engraftment, the mice were dosed with dasatinib or vehicle for 3 consecutive days, then were not treated for a period of 3 additional days. Subsequent to this treatment regimen, tumor burden was assessed and a profound decrease in tumor size in the dasatinib-treated mouse was observed (FIG. 22e). Conversely, the tumor burden in vehicle-treated mouse continued to increase, indicating that the augmentation in anti-tumor response was specific to dasatinib treatment.

**[0141]** In summary, dasatinib and ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies). First, these drugs were shown potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible. Second, expansion of CAR T cells in the presence of dasatinib or ponatinib was shown to prevent CAR tonic signaling and in turn enhance the functional capacity of CAR T cells. Lastly, providing short periods of CAR T cell “rest” in vivo via iterative drug dosing was shown to be one method by which CAR T cell exhaustion could be prevented or reversed and/or memory could be induced.

### Example III

**[0142]** This example describes the materials and methods for Example II.

#### Cells and Culture Conditions

**[0143]** NALM6-GL (acute lymphoblastic leukemia line, stably transfected with GFP and luciferase) and NALM6-

GL-GD2 (stably transfected to overexpress GD2 synthetase) cell lines were cultured in RPMI-1640. 293T and 143B cell lines were cultured in DMEM (Life Technologies). DMEM and RPMI-1640 were supplemented with 10% heat-inactivated FBS (Gibco, Life Technologies), 10 mM HEPES, 100 U/mL penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (Gibco, Life Technologies).

**[0144]** Primary human T cells were obtained from healthy donor buffy coats using a Pan T cell negative selection kit (Miltenyi Biotec). Donor T cells were then aliquoted and stored in Cryostor (StemCell Technologies) in liquid nitrogen. T cells were cultured in AimV (Gibco, Life Technologies) supplemented with 5% heat-inactivated FBS, 10 mM HEPES, 1% glutamax (Gibco, Life Technologies), and 100 u/uL recombinant human IL-2 (Peprotech). Dasatinib (Sigma Aldrich and Adooq Biosciences) or ponatinib (SelleckChem) were cultured at 1 uM unless otherwise specified.

#### Retroviral Production and T Cell Transduction

**[0145]** All retroviral supernatants were produced via transient transfection of the 293GP cell line. Briefly, 293GP cells were transfected via Lipofectamine 2000 (Life Technologies) with the plasmids encoding the CARs and RD114 envelope protein. Supernatants were collected at 48 and 72 hours post-transfection, aliquoted and stored at -80 C.

**[0146]** Upon thawing, T cells were activated at a 3:1 bead:cell ratio using anti-CD3/anti-CD28-coated magnetic beads (Dynabeads, Thermo Fisher) at a concentration of  $1 \times 10^6$  cells/mL. On days 2 and 3 post-activation, T cells were transduced with retrovirus encoding the CAR. Briefly, retrovirus was first spun onto retronectin-coated plates at 3000 rpm for 2 hours, after which T cells were transferred to the plates. On day 4 post-activation, magnetic beads were removed from culture, and T cells were cultured at  $0.5 \times 10^6$  cells/mL every day thereafter. Media supplemented with IL-2 and drug was changed every two days. Transduction efficiencies were routinely 70-90% for all CARs.

#### Flow Cytometry

**[0147]** All samples were analyzed with an LSR Fortessa (BD Bioscience) or a Cytotflex (Beckman Coulter) and data were analyzed using FlowJo. Cells were washed twice with PBS and labelled with stained at  $1 \times 10^6$  cells/mL in PBS, followed by two washes with FACS buffer (PBS supplemented with 2% FBS and 0.4% 0.5M EDTA). GD2 CARs were detected with the 14g2a anti-idiotypic antibody 1A7. CD19 CARs were detected with the FMC63 anti-idiotypic antibody 136.20.1. T cell phenotype was evaluated via: CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), PD-1 (eBioJ105, eBioscience), TIM-3 (F38-2E2, Biolegend), LAG-3 (3DS223H, eBioscience), CD45RA (L48, BD Biosciences), CCR7 (150503, BD Biosciences), CD62L (DREG-56, BD Biosciences), CD69 (FN50, Biolegend), and CD107a (H4A3, eBioscience). For co-culture assays in which CD107a was assessed, tumor cells and CAR T cells were co-cultured in the presence of 1:1000 monensin (eBioscience) and anti-CD107a for at least 6 hours. All FACS plots displaying CART cell phenotype data were pre-gated on CAR+ cells. For mock-transduced T cells, whole T cell populations were used for analysis.

#### Incucyte Assay

**[0148]** 50,000 NALM6-GL or NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:8 E:T ratio in 200



uL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate. Plates were loaded into the incucyte and 488 nm fluorescent images were acquired every 2 hours for 48-72 hours. GFP+ tumor cells were identified by size and fluorescence intensity masks, and the total integrated GFP intensity of all counted tumor cells was quantified for each individual well. Values were normalized to  $t=0$ , and replicate wells were averaged for data display.

[0149] For experiments in which HA-GD2.28z T cells were expanded in the presence of dasatinib, in some instances, drug was removed from the media 18-24 hours prior to the assay to allow CAR T cells to function in the presence of tumor antigen.

#### Cytokine Release Assay

[0150] 50,000 NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:1 E:T ratio in 200 uL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate. After 24 hours, supernatants were removed and stored at  $-20^{\circ}\text{C}$ . IL-2 and IFN $\gamma$  secretion was assessed via ELISA (Biolegend).

[0151] For experiments in which HA-GD2.28z T cells were expanded in the presence of dasatinib, in some instances, drug was removed from the media 18-24 hours prior to the assay to allow CAR T cells to function in the presence of tumor antigen.

#### Western Blot

[0152]  $2 \times 10^6$  CAR' cells were removed from culture, pelleted, and resuspended in 100 uL of RITA lysis buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with phosphatase and protease inhibitors (Thermo Fisher). After incubating for 30 minutes at  $4^{\circ}\text{C}$ , supernatants were cleared by centrifugation at 14,000 RPM for 20 minutes at  $4^{\circ}\text{C}$ . Protein concentration in the cleared lysates was measured by a colorimetric reaction (BioRad).

[0153] 1.5 ug of protein lysate was mixed with 6x loading buffer and loaded onto 10% SDS-PAGE gels assembled into a mini-protean electrophoresis systems (BioRad). Electrophoresis was performed in tris-glycine-SDS buffer (BioRad) at 100V for 20 minutes and later increased to 150V for 50 minutes. Protein transfer into Immobilon-FL PVDF membranes was performed at 100V for 1 hour in tris-glycine buffer (BioRad #1610771). Primary antibodies targeting CD3-zeta (Cell signaling), pY142-CD3-zeta (Cell Signaling), p44/42 MAPK (Erk1/2, Cell Signaling), p-p44/42 MAPK (p-ERK1/2, Cell Signaling), pSer473-Akt (D9E, Cell Signaling), and pan Akt (40D4, Cell Signaling) were used. The Odyssey (LI-COR) imaging system. LI-COR buffers, and LI-COR secondary antibodies (Goat Anti-Mouse IgG Antibody-800CW-Conjugated and Goat Anti-Rabbit IgG Antibody-680LT-Conjugated) were used for protein detection.

[0154] For CAR crosslinking, CAR T cells were incubated in 5 ug/mL anti-idiotypic (clone 1A7) plus 5 ug/mL goat anti-mouse Fab secondary (Jackson ImmunoResearch) or secondary alone for 5 minutes at  $37^{\circ}\text{C}$ . Cells were then quenched in ice cold PBS, pelleted at  $4^{\circ}\text{C}$  for 5 minutes, then lysed for western blot analysis.

[0155] In vivo experiments 6-8 week old NSG mice were engrafted with  $1 \times 10^6$  NALM6-GL-GD2 leukemia cells via intravenous injection. At day 4 post-engraftment,  $2 \times 10^6$

HA-GD2.28z CAR+ T cells were infused intravenously. NALM6-GL-GD2 tumor burden was evaluated using the Xenogen IVIS Lumina (Caliper Life Sciences). Mice were first injected intraperitoneally with 3 mg D-luciferin (Caliper Life Sciences) and then imaged 4 minutes later with an exposure time of 30 seconds, or, in cases where 30 seconds resulted in signal saturation, "auto" exposure was selected. Luminescence images were analyzed using Living Image software (Caliper Life Sciences).

[0156] 6-8 week old NSG mice were engrafted with  $0.5 \times 10^6$  143 B osteosarcoma cells intramuscularly. On day 3 post-engraftment,  $10 \times 10^6$  GD2.BBz or HA-GD2.28z were infused intravenously. Osteosarcoma burden was quantified via two-dimensional leg area measurements.

[0157] Mice treated with dasatinib (Adooq Biosciences) were injected intraperitoneally at a concentration of 50 mg/kg in water+10% Kolliphor HS 15 (Sigma Aldrich). Mice treated with vehicle were injected with an equivalent volume of water+10% Kolliphor HS 15.

[0158] Blood samples were taken via retro-orbital bleed and briefly stored in EDTA-coated microvettes (Kent Scientific). Spleens were mechanically disaggregated by passage through a 70- $\mu\text{m}$  filter (BD Biosciences). Both blood and spleen were lysed in ACK lysis buffer (Fisher Scientific) for 5 minutes and subsequently stained with surface marker antibodies for FACS analysis.

#### Construction of CAR Vectors

[0159] All CAR sequences were inserted into the MSGV retroviral backbone. Each CAR includes a signal peptide, single chain variable fragment (scFv), extracellular hinge region, transmembrane domain, intracellular co-stimulatory domain, and intracellular CD3 zeta domain.

#### Sequences

[0160] The nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv) is provided at FIG. 23.

[0161] The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv) is provided at FIG. 24.

[0162] The nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv) is provided at FIG. 25.

[0163] The nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv) is provided at FIG. 26.

[0164] Having now fully described the invention, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

#### INCORPORATION BY REFERENCE

[0165] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

#### EQUIVALENTS

[0166] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the inven-



tion is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within

the meaning and range of equivalency of the claims are intended to be embraced therein.

---

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 1794

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 1

atgacaagag ttactaacag cccctctctc caagctcact tacaggctct ctacttagtc	60
cagcacgaag tctggagacc tctggcggca gcctaccaag aacaactgga ccgaccggtg	120
gtacctcacc cttaccgagt cggcgacaca gtgtgggtcc gccgacacca gactaagaac	180
ctagaacctc gctggaaagg accttacaca gtcttctga cccccccac cgccctcaaa	240
gtagacggca tcgcagcttg gatacacgcc gccacgtga aggctgccga ccccgggggt	300
ggaccatcct ctgactgct cgagatgctt ctcttggtga caagccttct gctctgtgag	360
ttaccacacc cagcattcct cctgatccca gacatccaga tgacacagac tacatcctcc	420
ctgtctgcct ctctgggaga cagagtcacc atcagttgca gggcaagtca ggacattagt	480
aaatatttaa attggtatca gcagaaacca gatggaactg ttaaactcct gatctacat	540
acatcaagat tacactcagg agtcccatca aggttcagtg gcagtgggtc tggaacagat	600
tattctctca ccattagcaa cctggagcaa gaagatattg ccacttactt ttgccaacag	660
ggtaatacgc ttccgtacac gttcggaggg gggactaagt tggaaataac aggctccacc	720
tctggatccg gcaagcccgg atctggcgag ggatccacca agggcgaggt gaaactgcag	780
gagtcaggac ctggcctggt ggcgcctca cagagcctgt ccgtcacatg cactgtctca	840
ggggtctcat taccgacta tgggtgaagc tggattcgcc agcctccacg aaaggggtctg	900
gagtggctgg gagtaatatg gggtagtgaa accacatact ataattcagc tctcaaattcc	960
agactgacca tcatcaagga caactccaag agccaagttt tcttaaaaat gaacagtctg	1020
caaactgatg acacagccat ttactactgt gccaaacatt attactacgg tggtagctat	1080
gctatggact actgggggtca aggaacctca gtcaccgtct cctcagcggc cgcaattgaa	1140
gttatgtatc ctctcctta cctagacaat gagaagagca atggaaccat tatccatgtg	1200
aaagggaaac acctttgtcc aagtcacctt tttcccgga cttctaagcc cttttgggtg	1260
ctggtggtgg ttgggggagt cctggcttgc tatagcttgc tagtaacagt ggcctttatt	1320
atcttctggg tgaggagtaa gaggagcagg ctctgcaca gtgactacat gaacatgact	1380
ccccgcgcc ccggggccac ccgcaagcat taccagccct atgccccacc acgcgacttc	1440
gcagcctatc gctccagagt gaagttcagc aggagcgcag acgccccgc gtaccagcag	1500
ggccagaacc agctctataa cgagctcaat ctaggacgaa gagaggagta cgatgttttg	1560
gacaagagac gtggccggga ccctgagatg gggggaaagc cgagaaggaa gaaccctcag	1620
gaaggcctgt acaatgaact gcagaaagat aagatggcgg aggcctacag tgagattggg	1680
atgaaaggcg agcgccggag gggcaagggg cacgatggcc tttaccaggg tctcagtaca	1740
gccaccaagg acacctacga cgcccttcac atgcaggccc tgccccctcg ctaa	1794

-continued

<210> SEQ ID NO 2															
<211> LENGTH: 597															
<212> TYPE: PRT															
<213> ORGANISM: Artificial Sequence															
<220> FEATURE:															
<223> OTHER INFORMATION: synthetic															
<400> SEQUENCE: 2															
Met	Thr	Arg	Val	Thr	Asn	Ser	Pro	Ser	Leu	Gln	Ala	His	Leu	Gln	Ala
1				5					10					15	
Leu	Tyr	Leu	Val	Gln	His	Glu	Val	Trp	Arg	Pro	Leu	Ala	Ala	Ala	Tyr
			20					25				30			
Gln	Glu	Gln	Leu	Asp	Arg	Pro	Val	Val	Pro	His	Pro	Tyr	Arg	Val	Gly
			35				40					45			
Asp	Thr	Val	Trp	Val	Arg	Arg	His	Gln	Thr	Lys	Asn	Leu	Glu	Pro	Arg
	50					55					60				
Trp	Lys	Gly	Pro	Tyr	Thr	Val	Leu	Leu	Thr	Thr	Pro	Thr	Ala	Leu	Lys
65					70					75					80
Val	Asp	Gly	Ile	Ala	Ala	Trp	Ile	His	Ala	Ala	His	Val	Lys	Ala	Ala
				85					90					95	
Asp	Pro	Gly	Gly	Gly	Pro	Ser	Ser	Arg	Leu	Leu	Glu	Met	Leu	Leu	Leu
			100					105					110		
Val	Thr	Ser	Leu	Leu	Leu	Cys	Glu	Leu	Pro	His	Pro	Ala	Phe	Leu	Leu
			115				120					125			
Ile	Pro	Asp	Ile	Gln	Met	Thr	Gln	Thr	Thr	Ser	Ser	Leu	Ser	Ala	Ser
			130				135					140			
Leu	Gly	Asp	Arg	Val	Thr	Ile	Ser	Cys	Arg	Ala	Ser	Gln	Asp	Ile	Ser
145					150					155					160
Lys	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Asp	Gly	Thr	Val	Lys	Leu
				165					170					175	
Leu	Ile	Tyr	His	Thr	Ser	Arg	Leu	His	Ser	Gly	Val	Pro	Ser	Arg	Phe
			180					185						190	
Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Tyr	Ser	Leu	Thr	Ile	Ser	Asn	Leu
			195				200					205			
Glu	Gln	Glu	Asp	Ile	Ala	Thr	Tyr	Phe	Cys	Gln	Gln	Gly	Asn	Thr	Leu
			210				215					220			
Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Thr	Gly	Ser	Thr
225					230					235					240
Ser	Gly	Ser	Gly	Lys	Pro	Gly	Ser	Gly	Glu	Gly	Ser	Thr	Lys	Gly	Glu
				245					250					255	
Val	Lys	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu	Val	Ala	Pro	Ser	Gln	Ser
			260					265						270	
Leu	Ser	Val	Thr	Cys	Thr	Val	Ser	Gly	Val	Ser	Leu	Pro	Asp	Tyr	Gly
		275					280					285			
Val	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Arg	Lys	Gly	Leu	Glu	Trp	Leu	Gly
			290				295					300			
Val	Ile	Trp	Gly	Ser	Glu	Thr	Thr	Tyr	Tyr	Asn	Ser	Ala	Leu	Lys	Ser
305					310					315					320
Arg	Leu	Thr	Ile	Ile	Lys	Asp	Asn	Ser	Lys	Ser	Gln	Val	Phe	Leu	Lys
				325					330					335	
Met	Asn	Ser	Leu	Gln	Thr	Asp	Asp	Thr	Ala	Ile	Tyr	Tyr	Cys	Ala	Lys
			340					345					350		
His	Tyr	Tyr	Tyr	Gly	Gly	Ser	Tyr	Ala	Met	Asp	Tyr	Trp	Gly	Gln	Gly



-continued

355					360					365						
Thr	Ser	Val	Thr	Val	Ser	Ser	Ala	Ala	Ala	Ile	Glu	Val	Met	Tyr	Pro	
370					375					380						
Pro	Pro	Tyr	Leu	Asp	Asn	Glu	Lys	Ser	Asn	Gly	Thr	Ile	Ile	His	Val	
385					390					395					400	
Lys	Gly	Lys	His	Leu	Cys	Pro	Ser	Pro	Leu	Phe	Pro	Gly	Pro	Ser	Lys	
405					410					415						
Pro	Phe	Trp	Val	Leu	Val	Val	Val	Gly	Gly	Val	Leu	Ala	Cys	Tyr	Ser	
420					425					430						
Leu	Leu	Val	Thr	Val	Ala	Phe	Ile	Ile	Phe	Trp	Val	Arg	Ser	Lys	Arg	
435					440					445						
Ser	Arg	Leu	Leu	His	Ser	Asp	Tyr	Met	Asn	Met	Thr	Pro	Arg	Arg	Pro	
450					455					460						
Gly	Pro	Thr	Arg	Lys	His	Tyr	Gln	Pro	Tyr	Ala	Pro	Pro	Arg	Asp	Phe	
465					470					475					480	
Ala	Ala	Tyr	Arg	Ser	Arg	Val	Lys	Phe	Ser	Arg	Ser	Ala	Asp	Ala	Pro	
485					490					495						
Ala	Tyr	Gln	Gln	Gly	Gln	Asn	Gln	Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	
500					505					510						
Arg	Arg	Glu	Glu	Tyr	Asp	Val	Leu	Asp	Lys	Arg	Arg	Gly	Arg	Asp	Pro	
515					520					525						
Glu	Met	Gly	Gly	Lys	Pro	Arg	Arg	Lys	Asn	Pro	Gln	Glu	Gly	Leu	Tyr	
530					535					540						
Asn	Glu	Leu	Gln	Lys	Asp	Lys	Met	Ala	Glu	Ala	Tyr	Ser	Glu	Ile	Gly	
545					550					555					560	
Met	Lys	Gly	Glu	Arg	Arg	Arg	Gly	Lys	Gly	His	Asp	Gly	Leu	Tyr	Gln	
565					570					575						
Gly	Leu	Ser	Thr	Ala	Thr	Lys	Asp	Thr	Tyr	Asp	Ala	Leu	His	Met	Gln	
580					585					590						
Ala	Leu	Pro	Pro	Arg												
595																

<210> SEQ ID NO 3  
<211> LENGTH: 1482  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 3

atgcttctcc	tggtgacaag	ccttctgctc	tgtgagttac	cacaccacagc	attcctcctg	60
atcccagaca	tccagatgac	acagactaca	tcctccctgt	ctgcctctct	gggagacaga	120
gtcaccatca	gttcgagggc	aagtcaggac	attagtaa	atttaaattg	gtatcagcag	180
aaaccagatg	gaactgttaa	actcctgata	taccatacat	caagattaca	ctcaggagtc	240
ccatcaaggt	tcagtggcag	tggtcttgga	acagattatt	ctctcaccat	tagcaacctg	300
gagcaagaag	atattgccac	ttacttttgc	caacagggta	atacgcttcc	gtacacgttc	360
ggagggggga	ctaagttgga	aataacaggc	tccacctctg	gatccggcaa	gcccgatct	420
ggcgagggat	ccaccaaggg	cgaggtgaaa	ctgcaggagt	caggacctgg	cctggtggcg	480
ccctcacaga	gcctgtccgt	cacatgcact	gtctcagggg	tctcattacc	cgactatggt	540
gtaagctgga	ttcgccagcc	tccacgaaag	ggtctggagt	ggctgggagt	aatatggggt	600

-continued

agtgaaacca catactataa ttcagctctc aaatccagac tgaccatcat caaggacaac	660
tccaagagcc aagttttctt aaaaatgaac agtctgcaaa ctgatgacac agccatttac	720
tactgtgcca aacattatta ctacggtggt agctatgcta tggactactg gggtaagga	780
acctcagtca ccgtctctc agcgccgca accacgacgc cagcgccgcg accaccaaca	840
ccggcgccca ccacgcgtc gcagccctg tccctgcgc cagaggcgtg ccggccagcg	900
gcggggggcg cagtgcacac ggggggctg gacttcgcct gtgatatcta catctgggcg	960
cccttggcg ggacttgtgg ggctctctc ctgtcactgg ttatcacct ttactgcaa	1020
cggggcagaa agaaactcct gtatatattc aaacaacct ttatgagacc agtaciaact	1080
actcaagagg aagatggctg tagctgccga tttccagaag aagaagaagg aggatgtgaa	1140
ctgagagtga agttcagcag gagcgcagac gccccgcgt acaagcaggg ccagaaccag	1200
ctctataacg agctcaatct aggacgaaga gaggagtacg atgttttgga caagagacgt	1260
ggccgggacc ctgagatggg gggaaagccg agaaggaaga accctcagga aggcctgtac	1320
aatgaactgc agaaagataa gatggcggag gcctacagtg agattgggat gaaaggcgag	1380
cgccggaggg gcaaggggca cgatggcctt taccagggtc tcagtacagc caccaaggac	1440
acctacgacg cccttcacat gcaggccctg cccctcgct aa	1482
<210> SEQ ID NO 4	
<211> LENGTH: 493	
<212> TYPE: PRT	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthetic	
<400> SEQUENCE: 4	
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro	
1 5 10 15	
Ala Phe Leu Leu Ile Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser	
20 25 30	
Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser	
35 40 45	
Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly	
50 55 60	
Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val	
65 70 75 80	
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr	
85 90 95	
Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln	
100 105 110	
Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile	
115 120 125	
Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser	
130 135 140	
Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala	
145 150 155 160	
Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu	
165 170 175	
Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu	
180 185 190	



-continued

Glu	Trp	Leu	Gly	Val	Ile	Trp	Gly	Ser	Glu	Thr	Thr	Tyr	Tyr	Asn	Ser		
		195					200					205					
Ala	Leu	Lys	Ser	Arg	Leu	Thr	Ile	Ile	Lys	Asp	Asn	Ser	Lys	Ser	Gln		
		210					215				220						
Val	Phe	Leu	Lys	Met	Asn	Ser	Leu	Gln	Thr	Asp	Asp	Thr	Ala	Ile	Tyr		
225					230					235					240		
Tyr	Cys	Ala	Lys	His	Tyr	Tyr	Tyr	Gly	Gly	Ser	Tyr	Ala	Met	Asp	Tyr		
				245					250					255			
Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Ala	Ala	Ala	Thr	Thr		
			260					265						270			
Thr	Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala	Pro	Thr	Ile	Ala	Ser	Gln		
		275					280					285					
Pro	Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg	Pro	Ala	Ala	Gly	Gly	Ala		
		290				295					300						
Val	His	Thr	Arg	Gly	Leu	Asp	Phe	Ala	Cys	Asp	Ile	Tyr	Ile	Trp	Ala		
305					310					315					320		
Pro	Leu	Ala	Gly	Thr	Cys	Gly	Val	Leu	Leu	Leu	Ser	Leu	Val	Ile	Thr		
			325						330					335			
Leu	Tyr	Cys	Lys	Arg	Gly	Arg	Lys	Lys	Leu	Leu	Tyr	Ile	Phe	Lys	Gln		
			340					345					350				
Pro	Phe	Met	Arg	Pro	Val	Gln	Thr	Thr	Gln	Glu	Glu	Asp	Gly	Cys	Ser		
		355					360					365					
Cys	Arg	Phe	Pro	Glu	Glu	Glu	Glu	Gly	Gly	Cys	Glu	Leu	Arg	Val	Lys		
		370				375					380						
Phe	Ser	Arg	Ser	Ala	Asp	Ala	Pro	Ala	Tyr	Lys	Gln	Gly	Gln	Asn	Gln		
385					390					395					400		
Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg	Glu	Glu	Tyr	Asp	Val	Leu		
			405					410						415			
Asp	Lys	Arg	Arg	Gly	Arg	Asp	Pro	Glu	Met	Gly	Gly	Lys	Pro	Arg	Arg		
			420					425					430				
Lys	Asn	Pro	Gln	Glu	Gly	Leu	Tyr	Asn	Glu	Leu	Gln	Lys	Asp	Lys	Met		
			435					440				445					
Ala	Glu	Ala	Tyr	Ser	Glu	Ile	Gly	Met	Lys	Gly	Glu	Arg	Arg	Arg	Gly		
		450				455					460						
Lys	Gly	His	Asp	Gly	Leu	Tyr	Gln	Gly	Leu	Ser	Thr	Ala	Thr	Lys	Asp		
465					470					475					480		
Thr	Tyr	Asp	Ala	Leu	His	Met	Gln	Ala	Leu	Pro	Pro	Arg					
				485					490								

<210> SEQ ID NO 5  
<211> LENGTH: 1479  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic  
  
<400> SEQUENCE: 5  
  
atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccg ctttctgctg 60  
atccccgata tctgctgac ccagaccct ctgagcctgc ctgtgtctct gggcgatcag 120  
gccagcatca gctgcagatc cagccagagc ctggtgcacc ggaacggcaa cacctacctg 180  
cactggtatc tgcagaagcc cggccagagc cccaagctgc tgattcaciaa ggtgtccaac 240

-continued

cggttcagcg	gcggtgccga	cagatTTTct	ggcagcgget	cgggcaccga	cttcaccctg	300
aagatcagcc	gggtggaagc	cgaggacctg	ggcgtgtact	tctgcagcca	gtccaccac	360
gtgccccccc	tgacatttgg	cgccggaaca	aagctggaac	tgaagggcag	cacaagcggc	420
agcggcaagc	ctggatctgg	cgagggaagc	accaagggcg	aagtgaagct	gcagcagagc	480
ggccccctct	tgggtggaacc	tggcgctct	gtgatgatct	cctgcaaggc	cagcggcagc	540
tccttcaccg	gctacaacat	gaactgggtg	cgccagaaca	tcggaagag	cctggaatgg	600
atcggcgcca	tgcacctta	ctacggcggc	accagctaca	accagaagtt	caagggcaga	660
gccaccctga	ccgtggacaa	gagcagctcc	accgcctaca	tgcacctgaa	gtccctgacc	720
agcgaggaca	gcgccgtgta	ctactgcgtg	tccggcatgg	aatactgggg	ccagggcaca	780
agcgtgaccg	tgtcctctgc	ggccgcaacc	acgacgccag	cgccgcgacc	accaacaccg	840
gcgcccacca	tcgcgtcgca	gccccgtgcc	ctgcgcccag	aggcgtgccg	gccagcggcg	900
gggggcgcag	tgcacacgag	ggggctggac	ttcgctgtg	atatctacat	ctgggcgccc	960
ttggccggga	cttgtgggt	ccttctcctg	tactgggtta	tcaccttta	ctgcaaacgg	1020
ggcagaaaga	aactcctgta	tatattcaaa	caaccattta	tgagaccagt	acaaactact	1080
caagaggaag	atggctgtag	ctgccgattt	ccagaagaag	aagaaggagg	atgtgaactg	1140
agagtgaagt	tcagcaggag	cgcagacgcc	cccgcgtaca	agcagggcca	gaaccagctc	1200
tataacgagc	tcaatctagg	acgaagagag	gagtacgatg	ttttggacaa	gagacgtggc	1260
cgggaccctg	agatgggggg	aaagccgaga	aggaagaacc	ctcaggaagg	cctgtacaat	1320
gaactgcaga	aagataagat	ggcggaggcc	tacagtgaga	ttgggatgaa	aggcagcgcc	1380
cggaggggca	aggggcacga	tggcctttac	caggggtctca	gtacagccac	caaggacacc	1440
tacgacgccc	ttcacatgca	ggccctgccc	cctcgctaa			1479

<210> SEQ ID NO 6  
<211> LENGTH: 492  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic  
  
<400> SEQUENCE: 6  
  
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro  
1                  5                  10                  15  
  
Ala Phe Leu Leu Ile Pro Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser  
                  20                  25                  30  
  
Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser  
                  35                  40                  45  
  
Gln Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu  
                  50                  55                  60  
  
Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn  
65                  70                  75                  80  
  
Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr  
                  85                  90                  95  
  
Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val  
                  100                  105                  110  
  
Tyr Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala  
                  115                  120                  125



-continued

Gly	Thr	Lys	Leu	Glu	Leu	Lys	Gly	Ser	Thr	Ser	Gly	Ser	Gly	Lys	Pro
130						135					140				
Gly	Ser	Gly	Glu	Gly	Ser	Thr	Lys	Gly	Glu	Val	Lys	Leu	Gln	Gln	Ser
145					150				155						160
Gly	Pro	Ser	Leu	Val	Glu	Pro	Gly	Ala	Ser	Val	Met	Ile	Ser	Cys	Lys
			165						170					175	
Ala	Ser	Gly	Ser	Ser	Phe	Thr	Gly	Tyr	Asn	Met	Asn	Trp	Val	Arg	Gln
			180					185					190		
Asn	Ile	Gly	Lys	Ser	Leu	Glu	Trp	Ile	Gly	Ala	Ile	Asp	Pro	Tyr	Tyr
		195					200					205			
Gly	Gly	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	Lys	Gly	Arg	Ala	Thr	Leu	Thr
	210					215					220				
Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	His	Leu	Lys	Ser	Leu	Thr
225					230					235					240
Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	Val	Ser	Gly	Met	Glu	Tyr	Trp
			245						250					255	
Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Ala	Ala	Ala	Thr	Thr	Thr
			260					265					270		
Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala	Pro	Thr	Ile	Ala	Ser	Gln	Pro
		275					280					285			
Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg	Pro	Ala	Ala	Gly	Gly	Ala	Val
	290					295					300				
His	Thr	Arg	Gly	Leu	Asp	Phe	Ala	Cys	Asp	Ile	Tyr	Ile	Trp	Ala	Pro
305					310					315					320
Leu	Ala	Gly	Thr	Cys	Gly	Val	Leu	Leu	Leu	Ser	Leu	Val	Ile	Thr	Leu
				325					330					335	
Tyr	Cys	Lys	Arg	Gly	Arg	Lys	Lys	Leu	Leu	Tyr	Ile	Phe	Lys	Gln	Pro
			340					345					350		
Phe	Met	Arg	Pro	Val	Gln	Thr	Thr	Gln	Glu	Glu	Asp	Gly	Cys	Ser	Cys
		355					360					365			
Arg	Phe	Pro	Glu	Glu	Glu	Glu	Gly	Gly	Cys	Glu	Leu	Arg	Val	Lys	Phe
	370					375					380				
Ser	Arg	Ser	Ala	Asp	Ala	Pro	Ala	Tyr	Lys	Gln	Gly	Gln	Asn	Gln	Leu
385					390					395					400
Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg	Glu	Glu	Tyr	Asp	Val	Leu	Asp
			405						410					415	
Lys	Arg	Arg	Gly	Arg	Asp	Pro	Glu	Met	Gly	Gly	Lys	Pro	Arg	Arg	Lys
			420					425					430		
Asn	Pro	Gln	Glu	Gly	Leu	Tyr	Asn	Glu	Leu	Gln	Lys	Asp	Lys	Met	Ala
			435				440					445			
Glu	Ala	Tyr	Ser	Glu	Ile	Gly	Met	Lys	Gly	Glu	Arg	Arg	Arg	Gly	Lys
	450					455					460				
Gly	His	Asp	Gly	Leu	Tyr	Gln	Gly	Leu	Ser	Thr	Ala	Thr	Lys	Asp	Thr
465					470					475					480
Tyr	Asp	Ala	Leu	His	Met	Gln	Ala	Leu	Pro	Pro	Arg				
			485					490							

<210> SEQ ID NO 7  
<211> LENGTH: 2217  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic

---

-continued

---

&lt;400&gt; SEQUENCE: 7

atggaattcg gcctgagctg gctgttcctg gtggccatcc tgaagggcgt gcagtgcagc	60
agagatatcc tgctgacca gacccctctg agcctgcctg tgtctctggg cgatcaggcc	120
agcatcagct gcagatccag ccagagcctg gtgcaccgga acggcaacac ctacctgcac	180
tggatatctgc agaagcccgg ccagagcccc aagctgctga tccacaaggt gtccaaccgg	240
ttcagcggcg tgcccgacag attttctggc agcggctccg gcaccgactt caccctgaag	300
atcagccggg tggaagccga ggacctgggc gtgtacttct gcagccagtc caccacgtg	360
ccccccctga catttggcgc cggaacaaag ctggaactga aggggggagg cggatctggc	420
ggcggaggaa gtggcgagg gggatctgaa gtgaagctgc agcagtccgg cccagcctg	480
gtggaacctg ggcctctgt gatgatctcc tgcaaggcca gcggcagctc cttcaccggc	540
tacaacatga actgggtgcg ccagaacatc ggcaagagcc tggaatggat cggcgccatc	600
gaccctact acggcggcac cagctacaac cagaagttca agggcagagc caccctgacc	660
gtggacaaga gcagcagcac cgctacatg cacctgaagt ccctgaccag cgaggacagc	720
gccgtgtact actgcgtgtc cggcatgaag tactggggcc agggcacaag cgtgaccgtg	780
tctagcgcca agaccacccc ccctagcgtg tacggaagag tgacagtgtc ctctgccgag	840
cccaagagct gcgacaagac ccacacctgt ccccttgtc ctgcccctga gctgctggga	900
ggcccttcg tgttctgtt cccccaaaag cccaaggaca cactgatgat cagcagaacc	960
cccgaagtga cctgcgtggt ggtggacgtg tcccacgagg acccagaagt gaagttcaat	1020
tggtacgtgg acggcgtgga agtgacaaac gccaaagaaa agcccagaga ggaacagtac	1080
aacagcacct accgggtggt gtccgtgctg accgtgctgc atcaggattg gctgaacggc	1140
aaagagtaca agtgcaaagt gtccaacaag gccctgcctg ccccatcga gaaaaccatc	1200
agcaaggcca agggccagcc ccgcgaaccc caggtgtaca cactgcccc tagcagggac	1260
gagctgacca agaaccaggt gtccctgaca tgccctgtga agggcttcta cccctccgat	1320
atcgccgtgg aatgggagag caacggccag cccgagaaca actacaagac aaccctccc	1380
gtgctggaca gcgacggctc attcttctg tacagcaagc tgacagtgga taagtcccg	1440
tggcagcagg gcaacgtgtt cagctgctcc gtgatgcacg aggccctgca caaccactac	1500
accagaaaa gcctgtccct gagccccggc aagaaggacc ccaaagctag cttcgaaatt	1560
gaagttatgt atcctcctcc ttacctagac aatgagaaga gcaatggaac cattatccat	1620
gtgaaaggga aacaccttg tccaagtcct ctatttcccg gaccttcta gcccttttg	1680
gtgctggtgg tggttggggg agtcctggct tgctatagct tgctagtaac agtggccttt	1740
attattttct gggtgaggag taagaggagc aggtcctgc acagtgacta catgaacatg	1800
actccccgcc gccccgggccc caccgcaag cattaccagc cctatgcccc accacgcgac	1860
ttcgcagcct atcgctccag agtgaagttc agcaggagcg cagacgcccc cgcgtacaag	1920
cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt	1980
ttggacaaga gacgtggccg ggacctgag atggggggaa agccgagaag gaagaaccct	2040
caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagtgaatt	2100
gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggctcagt	2160
acagccacca aggacaccta cgacgcctt cacatgcagg ccctgcccc tcgctaa	2217



-continued

<210> SEQ ID NO 8  
<211> LENGTH: 738  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic  
  
<400> SEQUENCE: 8  
  
Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly  
1 5 10 15  
  
Val Gln Cys Ser Arg Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu  
20 25 30  
  
Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln  
35 40 45  
  
Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln  
50 55 60  
  
Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg  
65 70 75 80  
  
Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp  
85 90 95  
  
Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr  
100 105 110  
  
Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly  
115 120 125  
  
Thr Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
130 135 140  
  
Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu  
145 150 155 160  
  
Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser  
165 170 175  
  
Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys  
180 185 190  
  
Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser  
195 200 205  
  
Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser  
210 215 220  
  
Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser  
225 230 235 240  
  
Ala Val Tyr Tyr Cys Val Ser Gly Met Lys Tyr Trp Gly Gln Gly Thr  
245 250 255  
  
Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Gly  
260 265 270  
  
Arg Val Thr Val Ser Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr His  
275 280 285  
  
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val  
290 295 300  
  
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr  
305 310 315 320  
  
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu  
325 330 335  
  
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys  
340 345 350

Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser
		355					360					365			
Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys
	370					375					380				
Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile
385					390					395					400
Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro
				405					410					415	
Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu
			420					425					430		
Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn
		435					440					445			
Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser
	450					455					460				
Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg
465					470					475					480
Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu
				485					490					495	
His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Lys
			500					505					510		
Asp	Pro	Lys	Ala	Ser	Phe	Glu	Ile	Glu	Val	Met	Tyr	Pro	Pro	Pro	Tyr
		515					520					525			
Leu	Asp	Asn	Glu	Lys	Ser	Asn	Gly	Thr	Ile	Ile	His	Val	Lys	Gly	Lys
	530					535					540				
His	Leu	Cys	Pro	Ser	Pro	Leu	Phe	Pro	Gly	Pro	Ser	Lys	Pro	Phe	Trp
545					550					555					560
Val	Leu	Val	Val	Val	Gly	Gly	Val	Leu	Ala	Cys	Tyr	Ser	Leu	Leu	Val
				565					570					575	
Thr	Val	Ala	Phe	Ile	Ile	Phe	Trp	Val	Arg	Ser	Lys	Arg	Ser	Arg	Leu
			580					585					590		
Leu	His	Ser	Asp	Tyr	Met	Asn	Met	Thr	Pro	Arg	Arg	Pro	Gly	Pro	Thr
		595					600					605			
Arg	Lys	His	Tyr	Gln	Pro	Tyr	Ala	Pro	Pro	Arg	Asp	Phe	Ala	Ala	Tyr
	610					615					620				
Arg	Ser	Arg	Val	Lys	Phe	Ser	Arg	Ser	Ala	Asp	Ala	Pro	Ala	Tyr	Lys
625					630					635					640
Gln	Gly	Gln	Asn	Gln	Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg	Glu
				645					650					655	
Glu	Tyr	Asp	Val	Leu	Asp	Lys	Arg	Arg	Gly	Arg	Asp	Pro	Glu	Met	Gly
			660					665					670		
Gly	Lys	Pro	Arg	Arg	Lys	Asn	Pro	Gln	Glu	Gly	Leu	Tyr	Asn	Glu	Leu
		675					680					685			
Gln	Lys	Asp	Lys	Met	Ala	Glu	Ala	Tyr	Ser	Glu	Ile	Gly	Met	Lys	Gly
	690					695					700				
Glu	Arg	Arg	Arg	Gly	Lys</										



What is claimed is:

1. A method for preventing and/or reversing T cell exhaustion in a subject, the method comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor.

2. The method of claim 1, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

3. The method of claim 1, wherein the tyrosine kinase inhibitor is a Lck inhibitor.

4. The method of claim 1, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

5. The method of claim 1, wherein treatment increases secretion of IL-2 by T cells in the subject.

6. The method of claim 1, wherein treatment decreases apoptosis of T cells in the subject.

7. The method of claim 1, wherein treatment decreases expression of at least one T cell exhaustion marker selected from the group consisting of PD-1, TIM-3, and LAG-3.

8. The method of claim 1, wherein treatment increases expression of CD62L or CCR7.

9. The method of claim 1, wherein multiple cycles of treatment are administered to the subject.

10. The method of claim 7, wherein the tyrosine kinase inhibitor is administered intermittently.

11. The method of claim 1, wherein the tyrosine kinase inhibitor is administered for a period of time sufficient to restore at least partial T cell function then discontinued.

12. The method of claim 1, wherein the tyrosine kinase inhibitor is administered orally.

13. The method of claim 1, wherein the subject is human.

14. The method of claim 1, wherein the subject has a chronic infection or cancer.

15. The method of claim 1, wherein treatment is prophylactic.

16. A method for treating an immune system related condition or disease in a subject comprising administering to the subject genetically engineered T cells and a therapeutically effective amount of a tyrosine kinase inhibitor.

17. The method of claim 16, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

18. The method of claim 16, wherein the tyrosine kinase inhibitor is a Lck inhibitor.

19. The method of claim 16, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

20. The method of claim 16, wherein the tyrosine kinase inhibitor and the genetically engineered T cells are administered simultaneously and/or at different time points.

21. The method of claim 16, wherein the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.

22. The method of claim 16, wherein the genetically engineered T cells are selected from CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

23. The method of claim 16, further comprising administering to said subject one or more anticancer agents.

24. The method of claim 23, wherein the one or more anticancer agents is selected from a chemotherapeutic agent and radiation therapy.

25. A composition comprising a genetically engineered T cell population, wherein the genetically engineered T cell population was expanded in the presence of a tyrosine kinase inhibitor.

26. The composition of claim 25, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

27. The composition of claim 25, wherein the tyrosine kinase inhibitor is a Lck inhibitor.

28. The composition of claim 25, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

29. The composition of claim 25, wherein the genetically engineered T cell population is selected from CART cell population, a population of genetically engineered TCR expressing T cells, a population of genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, a population of genetically engineered T cells configured for transduced T-cell therapy, and/or a population of viral specific T cells reengineered with a TCR or CAR.

30. A method of generating a population of genetically engineered T cells resistant to T cell exhaustion, comprising expanding a population of genetically engineered T cells in the presence of a tyrosine kinase inhibitor.

31. The method of claim 30, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

32. The method of claim 30, wherein the tyrosine kinase inhibitor is a Lck inhibitor.

33. The method of claim 30, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

34. The method of claim 30, wherein the population of genetically engineered T cells is selected from CAR T cell population, a population of genetically engineered TCR expressing T cells, a population of genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, a population of genetically engineered T cells configured for transduced T-cell therapy, and/or a population of viral specific T cells reengineered with a TCR or CAR.

35. A method of treating an immune system related condition or disease, comprising administering to the subject a genetically engineered T cell population that were expanded in the presence of a tyrosine kinase inhibitor.

36. The method of claim 35, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

37. The method of claim 35, wherein the tyrosine kinase inhibitor is a Lck inhibitor.

38. The method of claim 35, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

39. The method of claim 35, wherein the genetically engineered T cell population is selected from CAR T cell population, a population of genetically engineered TCR expressing T cells, a population of genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, a population of genetically engineered T cells configured for transduced T-cell therapy, and/or a population of viral specific T cells reengineered with a TCR or CAR.

40. The method of claim 35, wherein the subject is undergoing an adoptive T cell therapy.

41. The method of claim 40, wherein the adoptive T cell therapy is a CAR T-cell therapy.

42. The method of claim 40, wherein the adoptive T cell therapy is a transduced T-cell therapy.

**43.** The method of claim **40**, wherein the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.

**44.** The method of claim **35**, wherein the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.

**45.** The method of claim **35**, further comprising administering to said subject one or more anticancer agents.

**46.** The method of claim **45**, wherein the one or more anticancer agents is selected from a chemotherapeutic agent and radiation therapy.

**47.** A method for preventing and/or reversing toxicity related to genetically engineered T cell administered to a subject, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor.

**48.** The method of claim **47**, wherein the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.

**49.** The method of claim **47**, wherein the tyrosine kinase inhibitor is a Lck kinase inhibitor.

**50.** The method of claim **47**, wherein the tyrosine kinase inhibitor is dasatinib or ponatinib.

**51.** The method of claim **33**, wherein the genetically engineered T cells are selected from CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.

**52.** The method of claim **47**, wherein the subject is undergoing an adoptive T cell therapy.

**53.** The method of claim **52**, wherein the adoptive T cell therapy is a CAR T-cell therapy.

**54.** The method of claim **52**, wherein the adoptive T cell therapy is a transduced T-cell therapy

**55.** The method of claim **52**, wherein the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.

**56.** The method of claim **47**, wherein the toxicity related to genetically engineered T cell administered to a subject is cytokine release syndrome.

**57.** The method of claim **47**, wherein the toxicity related to genetically engineered T cell administered to a subject is on-target off tumor toxicity or off-target off-tumor toxicity.

\* \* \* \* \*